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ABSTRACT 
DETERMINATION OF THE BIOLOGICAL FUNCTIONS OF UNDEFINED DOMAINS OF 
VEEV NSP2 
Andrew Michael Skidmore 
April 9, 2021 
Alphaviruses are positive sense, single strand, RNA viruses. These viruses occur 
on every populated continent. Alphaviruses are divided into two clades, the New-World 
and Old-World viruses. The New-World viruses include Eastern (EEEV), Western 
(WEEV), and Venezuelan equine encephalitis viruses (VEEV), and cause neuroinvasive 
disease. The Old-World viruses include Chikungunya (CHIKV) and Ross River viruses 
(RRV), and typically cause multijoint arthralgia. There are currently no approved antiviral 
therapeutics or vaccines for any alphavirus, making them a high priority for antiviral drug 
design and discovery. A benzamidine inhibitor (ML336) of VEEV was characterized, and 
determined to inhibit replication of VEEV RNA during infection of BHK-21 cells, a 
fibroblast model. This activity was due a loss of synthesis of new viral RNA. This 
compound had no effect on RNA synthesis in uninfected cells, making it a promising 
target for therapeutic development. The inhibitory activity of ML336 was highly specific 
for VEEV, having no effect on RNA synthesis of CHIKV. A potential interaction between 
ML336 and the VEEV nsPs was examined, but these results were inconclusive. ML336 
and related compounds were used to generate resistant mutant VEEV. These isolates 
were sequenced and it was revealed that mutations were concentrated in a region of 
nsP2 of unknown function. Analysis of these mutant viruses revealed delayed growth, 
RNA synthesis, and translation of viral proteins in BHK cells. There was also a growth 
delay seen in SH-SY5Y cells, a model of neuronal infection. These findings indicate that 
this region of nsP2 is likely involved in RNA synthesis of VEEV, and shows promise as a 
target of antiviral drug development. 
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Alphaviruses are positive sense, single stranded, RNA viruses in the family 
Togaviridae, which are classified as members of the domain Riboviria1. The alphaviruses 
currently encompass more than thirty members that infect a wide range of host and 
vector species, both terrestrial and aquatic. These viruses are widely dispersed 
geographically as well, with at least one alphavirus being present on every populated 
continent23–6. These viruses are currently emerging into naïve populations making them 
an important group of pathogens as there are currently no treatments or vaccines for 
alphaviral disease.  
The geographic distribution of the alphaviruses has resulted in the historical 
classification of the viruses based on where they were initially isolated. The Old-World 
viruses were initially isolated in the Eastern hemisphere, primarily in Africa. The New-
World viruses were isolated in the Americas, and have a more diverse native 
distribution, with members being found from southern Canada all the way to Argentina. 
These two clades are also regarded as having distinct symptoms in the host.  
The Old-World viruses generally cause arthralgia and fever, with some also 
causing a rash7. There is some recent evidence that Old-World members may be able to 
cause encephalitis as well, with the adaptation of neurologically invasive Sindbis (SINV) 
virus in the lab, as well as its association with rare cases of viral encephalitis in Europe8–
10. Neurological invasion is a common symptom of the New-World alphaviruses, with the
three most prominent members of this clade: Eastern (EEEV), Western (WEEV), and 
Venezuelan Equine Encephalitis viruses (VEEV), demonstrating high levels of 
neurological pathogenicity7. Recent research has indicated that this division may be less 
stringent than previously thought, as many recently discovered New-World viruses do 
not cause detectable disease in humans or other host animals at all11. Additionally, 
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several New-World viruses which may display pathogenicity that is more in line with that 
of the Old-World viruses, such as Mayaro virus2,12.  
Alphaviral Disease 
The following section will discuss the diseases that are caused by alphaviruses in 
the human population.  
The Old-World virus of most concern is Chikungunya virus (CHIKV), which has 
recently expanded into naïve populations across Asia, southern Europe, and most 
dramatically in the Caribbean3–6. This has resulted in CHIKV becoming endemic in 
several regions where it previously had never achieved local transmission. The primary 
risk of these viruses is the sustained arthralgia that can last for months, with one study in 
Mexico indicating that over a third of confirmed CHIKV cases have arthralgia twelve 
months after acute disease13. Similar instances of long term pain have been seen in 
other family members as well, such as Ross River virus14.  
The New-World alphaviruses generally cause more severe disease than the Old-
World viruses, however the three most common (EEEV, WEEV, VEEV) are noted for 
displaying a high rate of asymptomatic infection11. This asymptomatic infection rate does 
vary between the three viruses and in the two primary populations of interest, equids and 
humans11. Disease is also generally more severe in equid hosts than in humans7. 
Disease generally reduces in severity comparing EEEV to WEEV to VEEV, with EEEV 
having the highest reported rate of neurological involvement and lethality, VEEV having 
the least, and WEEV falling between the two11. However VEEV has historically caused 
the largest and largest number of outbreaks affecting both human and equid populations 
resulting in many thousands of human cases and equid deaths11,15.  
4 
EEEV is the most severe of the New World alphaviruses with case fatality rates 
in some cases estimated to be above 60%16 and infection results in death or permanent 
neurological sequelae in a large majority of symptomatic cases17. The virus remains 
uncommon in the human population, with only in a handful of reported cases every year 
in the United States18. There has recently been an uptick in cases of EEEV reported to 
the CDC, with almost 40 cases reported in 2019, a more than fivefold increase from 
201818. 
WEEV is of moderate pathogenicity, with a case fatality and rate of neurological 
involvement between that of EEEV and VEEV. While the virus has caused instances of 
severe human disease, its occurrence in the human population is quite low11 and has 
been declining for many years since its initial discovery in the 1930s. In fact, since 1964 
there have been less than 700 cases of WEEV reported in the United States, averaging 
out to less than 12 cases a year19. And there has not been a reported case of human 
WEEV disease in the United States since 199820.  
VEEV is the least severe of the encephalitic alphaviruses. Conversely it is also 
the virus of most concern for two reasons. First, unlike the other encephalitic 
alphaviruses VEEV has a history of causing large outbreaks in large portions of South 
and Central America, causing thousands of human cases, with hundreds of those having 
neurological involvement15. Second, VEEV is also highly transmissible via the aerosol 
route, making it a concern for both accidental exposure as well as purposeful misuse21. 
This high level of transmissibility made VEEV a target for bioweapon by both the United 
States and former Soviet Union during the Cold War, leading to its classification as a 
select agent, a classification it shares with EEEV22. VEEV generally causes a mild febrile 
illness, that occasionally results in encephalitic infection, with encephalitic infection 
resulting in death in approximately 10% of cases7. Cases of VEEV with neurologic 
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involvement are often fatal, and those patients that do survive are likely to suffer from 
long term sequelae23.  
There are currently no treatments or preventive measures available for any 
alphavirus, making them targets of antiviral drug and vaccine development. The 
pathology of alphaviruses is outlined in Figure 1.  
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Figure 1. Alphaviral disease. Alphaviruses of both the Old and New-World clades are 
known to cause febrile illness in most cases, and many of these cases do not progress 
further. In severe cases, the Old-World viruses can cause long lasting symptoms, 
primarily a multijoint arthralgia that can last for several months. However, the Old-World 
viruses are rarely fatal. Severe cases of the New-World viruses can cause multiple 
neurological symptoms. In the case of neuroinvasion the New-World viruses are 
frequently fatal, and survivors generally have permanent sequalae.  
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Natural Transmission of the Alphaviruses 
Alphaviruses are vector borne viruses that generally require the use of an 
intermediate species to transmit to a naïve vertebrate host7, and this transmission cycle 
is outlined in Figure 2. Due to this cycle, the viruses must efficiently infect and replicate 
in multiple species. Alphaviruses infect a wide variety of both vector and hosts, and the 
species infected are specific for each virus. The reservoir species for VEEV are primarily 
various rodents including cotton rats24,25 Individual alphaviruses are often able to infect 
multiple different vector species, with separate species being involved in endemic 
maintenance and others being necessary to cause epidemic and epizootic 
transmission26. Epidemic strains of VEEV have been isolated from mosquito species of 
several genera including Aedes, Ochlerotatus, and Psorophora24,25. These vectors 
where epidemic strains are found are commonly referred to bridge vectors, as these 
species have increase promiscuity in their feeding habits, making them more likely to 
infect a non-reservoir species, such as a human or an equid27–29. The feeding habits of 
vector species, as well as the natural range of vector and reservoir species are the 
primary determinants of the geographic range of any given alphavirus. 
The virus will first enter the mosquito or other vector through a blood meal that is 
taken from an infected host. The virus will then encounter the cells of the mosquito 
midgut, before passing into the hoemocel, the circulatory system of the mosquito. 
Eventually virus will arrive in the salivary glands where it replicates to high levels and is 
transmitted to the next vertebrate host during a blood meal30,31. Not only does vector 
transmission complicate control of these viruses, but infection of the mosquito is an 
important selection process, and different strains of these viruses can behave differently 
in the vector. In particular, epidemic VEEV strains behave very differently in the 
mosquito than those are isolated from enzootic infection30–32.  
8 
Upon blood meal from an infected mosquito, the alphavirus is injected into the 
skin of a naïve host. As these viruses have various cellular tropisms that will result in 
differing pathologies, here the general series of events that will occur for the infection of 
a susceptible and permissive host cell will be described.  
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Figure 2. The transmission cycle of alphaviruses. A) Alphaviruses are maintained in 
nature by cycling between a host species, typically a bird or small mammal, and a 
mosquito vector species. B) Spillover events often occur into livestock, which reach high 
viral titers and readily transmit the virus to additional vectors. In the case of the New 
World viruses this infection almost always leads to death. C) Typically, after infection of 
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livestock, humans that work in close association with these animals can also be infected 
by vector species. Humans are regarded as dead end hosts for VEEV. In humans these 
infections may lead to disease, and, in severe cases, death.  
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Alphaviral replication 
After inoculation into the vertebrate host alphaviruses enter permissive and susceptible 
host cells to manufacture new virions. This process is here described in detail, and a 
summary can be found in Figure 4. 
Receptor-mediated endocytosis 
The primary mechanism by which alphaviruses enter naïve host cells is via 
receptor mediated endocytosis33. There have been multiple different suggested 
receptors for cellular entry33. Two important receptors are DC-SIGN and L-SIGN, which 
are likely involved in the myeloid cell tropism displayed by VEEV, which is known to 
infect dendritic cells early in infection34. Multiple other receptors have been found, and  
continue to be found in recent work35.CRISPR has been used to great effect in the 
search for additional alphaviral receptors, with Mxra8 being found to be important for 
multiple alphaviurses36, and LDLRAD3 having been described as a receptor for VEEV 
specifically37.  Heparin sulfate has also been found to be a binding partner for some of 
these viruses, and is ubiquitously expressed33. However, it has been found that viruses 
that have not been adapted to cell culture have less affinity for heparin sulfate38,39,40. This 
indicates that it is likely that the amount of heparin sulfate binding that has been reported 
is an artifact of cell culture adaptation of virus that has been produced and expanded in 
in vitro systems.  
After receptor binding the alphaviruses are then transported into the cell via 
clathrin mediated endocytosis4133, resulting in a virus containing endosome passing 
through the stages of acidification and maturation. The New-World viruses, including 
VEEV, remain in the vacuoles until they reach the endosome stage, whereas the Old-
World viruses escape from the early endosomal compartment42. 
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There is some evidence that alphaviruses may demonstrate alternative entry 
strategies, such as direct entry at the host cell plasma membrane4344. This has been well 
characterized in CHIKV as well, with research indicating that even though an 
acidification step is required, it can occur in a manner that is independent of the activity 
of clathrin45. However, the importance of this entry method remains unclear. 
Fusion/ Uncoating and RNA release 
Fusion of the viral and host cell membranes is achieved by the activity of the E1 
protein, and expression of E1 without the other glycoproteins is enough to mediate viral 
membrane fusion46,47. This fusogenic activity is initially prevented by the interaction of E1 
with E2, but this interaction is disrupted at low pH33,48.  
After fusion the nucleocapsid core is released into the cytoplasm of the cell. The 
disassembly of the nucleocapsid is enhanced by the low pH environment, which may be 
caused by membrane pores induced by E14950,5152. After escape from the endosome, the 
nucleocapsid interacts with ribosomes, which disassemble the capsid in a non-catalytic 
manner53. This disassembly appears to be dependent on conserved sequences in the 
capsid protein54. These steps have only been outlined so far using SINV and SFV.  
Translation and processing of the nsPs 
As positive sense, single-stranded RNA viruses, the alphavirus genome requires 
no additional processing to be available as an mRNA for translation by the host cell 
ribosomes. The genome has both a 5’ methyl cap and a 3’ poly A tail, allowing for 
normal recruitment of initiation and elongation factors to begin translation7. The initial 
step of viral replication is the translation of the nonstructural polyprotein, which contains 
the proteins which are responsible for the replication of the viral RNA. The viral nsPs are 
numbered in the order that they occur in the genome from 5’ to 3’, 1-4. The genomic 
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organization of VEEV can be found in Figure 4. The initial polyprotein is translated as 
either nsP123 or nsP1234, depending on read through of a stop codon that may or may 
not be present in the genome depending on the alphavirus in question55,56,57.  
After the initial translation of these proteins, they undergo tightly controlled cleavage 
events that result in the formation of multiple intermediates as well as the formation of 
the final mature replicase complex nsP1/2/3/458,59. This fully cleaved, mature complex is 
highly stable. Control of this cleavage process is important as it controls the levels of 
viral RNA species that are present at different times during infection60,61. This cleavage 
process appears to have unique regulatory features such as having morphological 
cleavage recognition instead of sequence specificity62. This regulatory process is highly 
important to viral biology as altering it leads to attenuation63. Proper cleavage is also 
important to immune evasion, as viruses with incomplete cleavage result in alterations of 
the viral RNA species prevalences, increasing Type I interferon induction as well as 
sensitivity of the viruses to interferon64. 
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Figure 3. The genetic structure of VEEV. VEEV has a 12kb, linear, positive-sense 
genome. The genome has two open reading frames, the nonstructural and the structural. 
The nonstructural open reading frame encodes the four nonstructural proteins, which are 
responsible for replication of the viral RNA. The structural open reading frame encodes 
for the E proteins and capsid as well as the 6K and TF proteins. The capsid and E 
proteins form the structure of the viral particle.  
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Viral RNA Replication 
The process of viral RNA synthesis is outlined in Figure 5. To make additional 
molecules of RNA genome, the virus is required to first transcribe the positive-sense 
genome into negative-sense template strand. This activity is performed by the partially 
cleaved polyprotein nsp123/461. However, nsP2 has protein cleavage activity which 
rapidly degrades the polyprotein into its constitutive parts. This initially produces 
intermediate forms of the replicase complex that are short lived and produce both 
negative and positive-sense RNA60,61. The final cleavage between nsP2 and nsP3 leads 
to the formation of the mature replicase complex nsP1/2/3/4 which produces only 
positive-sense RNA58,59,65. This self-proteolytic behavior creates a distinct expression 
profile of the viral RNA. Initially the immature forms of the complex produce higher levels 
of negative-sense RNA. As the complex is processed the synthesis of negative-sense 
RNA is reduced and eventually eliminated. This causes most negative-sense RNA to be 
produced early in infection, as well as less negative-sense RNA being produced 
overall66.Following cleavage and assembly of the mature replicase complex, RNA 
synthesis converts to the synthesis of positive-sense genomic and subgenomic RNA67. 
The positive-sense genomic RNA functions primarily as the genetic material of 
the next generation of virus, as well as being translationally activity in the cell to produce 
additional nonstructural proteins. However, recent work has indicated that the genomic 
RNA may have biological functions in addition to this, as increasing the amount of non-
capped genomic RNA that is produced during infection leads to a decrease in viral 
fitness68. The other positive-sense viral RNA that is produced is the subgenomic RNA. 
This small RNA is produced from a separate promoter and encodes for the structural 
genes of the virus55.   
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Localization of genome replication 
Alphaviruses demonstrate a sequestration of their replication to intracellular 
membranes, which is similar to other RNA viruses which also largely replicate in and on 
membranous structures69–71. The alphaviruses utilize microinvaginations called 
spherules69. These are sites where the viral RNA has been found to localize in infected 
cells72,73. It has been confirmed in vitro that these structures contain viral RNA synthetic 
activity through the use of purified spherules to synthesize viral RNA74. It has been 
recently determined that the initial formation of the spherules is dependent solely on the 
activity of the nsPs with no requirement for viral RNA being present75. However, the size 
of the individual spherules is dependent on the length of the RNA that is transcribed 
within, which appears to be a feature unique to alphaviruses76. 
Spherules were initially identified on large, endosomal-like compartments in 
infected cells. In several of these viruses these spherules form at the plasma membrane 
and later traffic to intracellular compartments77.  This localization has not yet been fully 
characterized in VEEV. In vertebrate cells, the movement of the spherules away from 
the plasma membrane is dependent on the activation of PI3K-Akt-mTOR, and reduction 
of this activation is associated with an increased proportion of the spherules remaining at 
the cellular membrane78 
Translation of the structural genes 
The structural genes of the alphaviruses are produced via translation of the 
subgenomic RNA. The initial gene product is a polyprotein that contains the capsid, E 
proteins, 6K, and TF proteins protein557. The capsid protein contains a serine protease 
domain and uses this to rapidly cleave itself from the other structural genes55. The 
capsid protein forms the nucleocapsid core and is responsible for binding to and 
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packaging viral RNA61, this interaction is mediated by the size and charge of the RNA 
molecule79. In addition to the role that it plays in virion structure, the capsid of 
alphaviruses also has biological functions involved in viral pathogenesis. In the New-
World alphaviruses the capsid protein is able to block the nuclear pores and thus 
prevent the translation of new cellular protein, enhancing viral pathogenesis, cytopathic 
effect, and assisting in immune evasio80,81. This protein synthesis inhibition functions in 
tandem with the nsPs which actively inhibit the synthesis of cellular proteins82. 
After cleavage of the capsid protein, the glycoproteins are translated into the 
endoplasmic reticulum, and pass through the Golgi apparatus before being embedded 
into the plasma membrane of the cell55. These proteins are also highly post-
translationally modified via glycosylation and palmitoyaltion55.  
Packaging of the viral RNA and release of the virion 
After translation of the structural proteins, the viral RNA must be packaged into 
the virion and then released to infect new host cells. The RNA and capsid undergo 
interactions due primarily to molecule size and charges, resulting in nucleocapsid like 
structures occurring in the cytoplasm55,79,83. Alphaviruses bud directly from the plasma 
membrane of the infected cell7. However, it is unclear how this budding process is 
initiated83. It has been found that both the preformed nucleocapsid like structures and 
the glycoproteins are able to drive budding83,84. However, when either of the functions 
occurs independently of the other, there is a marked reduction in efficiency, indicating 
that it is likely that these two mechanisms interact to allow for the maximal budding of 
virions84. 
Transport of the structural proteins to the plasma membrane requires the host 
secretory system84. However the exact proteins that are used remain unknown84. 
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Release of virions can also be inhibited by host proteins. In particular tetherin has been 
shown to prevent the release of virions from infected cells84. The general replication of 
alphaviruses is outlined in Figure 4 below.  
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Figure 4. The replication cycle of alphaviruses. The virion enters a susceptible cell via 
receptor mediated endocytosis, and due to pH changes of the endosome releases its 
RNA into the cytoplasm of the host cell. The positive sense genomic RNA is first used by 
ribosomes to translate the viral nsPs as a polyprotein. The polyprotein will undergo 
cleavage events that control the synthesis of the viral RNA species. This RNA synthesis 
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occurs in membrane invaginations that are termed spherules. These spherules protect 
the viral RNA and nsPs from detection by the host cell. Late in infection the structural 
genes are synthesized. The capsid will form into nucleocapsid cores as it packages the 
viral RNA, and the glycoproteins are transported to the cell membrane. The 
nucleocapsid cores translocate to the cellular membrane where they bud off, collecting 
their envelope and glycoproteins and forming new infectious virus.  
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Figure 5. RNA synthesis of alphaviruses. This RNA synthesis activity is carried out in 
spherules on the membranes of cellular organelles. After release into the cytoplasm the 
genomic RNA is used to synthesize the initial nonstructural polyprotein. nsP2 initially 
cleaves between nsP3 and 4 leading to nsP123/4, which synthesizes primarily negative-
sense template RNA. The protein undergoes rapid cleavage through intermediate states 
to reach the final replicase complex nsP1/2/3/4. This complex synthesizes new positive-
sense genomic and subgenomic RNA and can no longer synthesize negative-sense 
RNA. The genomic RNA is used to synthesize additional genomes and is packaged into 
progeny virions. The subgenomic RNA is used to synthesize the structural genes that 
from the new virions.  
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Functions of the alphaviral nonstructural proteins 
The alphaviruses make four nonstructural proteins. These proteins are 
responsible for viral RNA replication as well as many other enzymatic functions. The 
nonstructural proteins are also intimately involved in the pathogenesis of the 
alphaviruses. The functions of these proteins will now be described in greater detail. 
While the functions of the nsPs are highly conserved, differences between the Old and 
New-World viruses will be indicated when necessary. 
Nonstructural protein 1 
NsP1 is the capping enzyme for the viral genomic RNA, and this activity occurs 
independent of the activities of the other nsPs85. The activity of this protein has only 
recently been examined in VEEV, having previously been studied only in Old-World 
viruses. This was also the first time that each individual step, including the final guanyl 
transfer, has ben detected86. The steps occur as follows. 1) The transfer of a methyl 
group from S-adenosylmethionine to position N7 of a molecule of GTP is catalyzed 2) 
nsP1 receives the methyl-GTP becoming guanylated, releasing pyrophosphate in the 
process 3) the 7 methyl-GMP is transferred to the 5’ end of the target RNA86,87. For this 
reaction to occur properly, the RNA being capped must have had its 5’ terminal 
phosphate removed by nsP288 NsP1 is also responsible for the anchoring of the viral 
replicase complex to cellular membranes which are the site of RNA replication, and this 
activity is required for capping to be carried out as well89–91. Very recently a cryo-em 
structure was published that showed how nsP1 influences the structure of the 
membrane spherules and potentially controls entry and exit of materials92. NsP1 was 
found to form a ring-like structure that appears to act as a gate and controls entry and 
exit from the spherule92. The nsPs are also responsible for the formation of the 
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spherules and this can occur in the absence of viral RNA75 however the viral RNA 
determines the spherule size76. 
Nonstructural protein 2 
NsP2 is a multifunctional protein with many described functions and multiple 
domains with discreet enzymatic activities. First, nsP2 is responsible for host cell 
transcriptional shutoff in the Old-World viruses, and loss of this phenotype reduces viral 
cytotoxicity80,93. In the New-World viruses this activity is instead carried out by the capsid 
protein, and nsP2 is responsible for shutoff of host cell protein synthesis, and may have 
a role in packaging of viral RNA80,81,94,95. In VEEV this translational shut down provides 
resistance to a pre-existing antiviral state94.  
There are three recognized domains in nsP2. The N-terminal regions contains a 
helicase domain, and NTPase activity that serves to provide energy for the helicase96,97. 
This same region also has RNA 5’-triphosphatase activity which prepares RNA for 
capping, allowing for translation and packaging in virions88. The N terminal region of the 
protein including the helicase domain has recently been crystalized98. The most 
interesting feature was the large number of accessory domains that were present, as 
these domains had not previously been predicted by structural modeling. In particular 
the so called stalk domain, which based upon our own research appears to have an 
important function in viral RNA synthesis66.  
Large portions of the N-terminal region of nsP2 remain poorly characterized. 
Studies have implicated that in VEEV this region may be important to packaging of the 
viral genome95. However, in SINV this a transposon insertion approach using the 
sequence for GFP found that region was involved in the cleavage between nsP2 and 
nsP3, controlling the ratio of genomic and subgenomic RNA, and regulation of RNA 
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synthesis99. This range of phenotypes indicates that these regions are highly important 
to these viruses, but further characterization and research is needed. 
NsP2 also contains a cysteine protease domain that is responsible for the 
cleavage of the nsPs from the polyprotein into its constitutive members100–102. As 
described earlier, this cleavage is responsible for the transition from the synthesis of 
negative-sense viral RNA to positive-sense viral RNA61,103. The protease has also been 
shown to target cellular proteins, a common feature of viral proteases, and this is related 
to resistance to innate immune responses104.  
Lastly, nsP2 contains a putative methyltransferase domain that was predicted 
due to the structure of the protein102. However, it is predicted to be inactive as it lacks the 
active site residue necessary for activity85. Recently though, there has been work that 
indicates this domain may play a role in interferon shutoff due to its interaction with 
signal transducer and activator of transcription proteins 1 (STAT1)105. This activity 
appears to be mediated by enhancing the nuclear export of STAT1, which prevents the 
magnification of downstream immune signaling, including the interferon response105 
Nonstructural protein 3 
NsP3 is poorly understood, but mutations within this protein have resulted in 
defects in both negative-sense and subgenomic RNA synthesis106.  
NsP3 contains a macrodomain with both adenosine diphosphate ribose (ADPr) 
binding and hydrolase activity85,107108. This ADP ribosylase activity is necessary for 
infection of neural cells and the hydrolase activity results in an increase in replicase 
complexes109. In a SINV model, reductions in hydrolase activity led to reduced 
neurovirulence while increases in ADP ribosylase activity increased neurovirulence110.  
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NsP3 also contains the highly conserved alphavirus unique domain, or AUD85. 
This domain is maintained across all alphaviruses85. Recent work has indicated that it 
potentially has many functions in CHIKV, particularly in subgenomic RNA replication111. 
Disruption of the AUD resulted in decreased infectivity, potentially due to decreased 
interaction with the viral RNA and the subgenomic promoter111. 
The last feature of note in nsP3 is the hypervariable domain or HVD. This domain 
is so varied that it can be distinct between strains of a single viral species, such as in 
VEEV112. This region is tolerant of significant mutation and even deletion, which is 
unique compared to the rest of the alphaviral genome113. Natural duplications and 
insertions in this region can even have positive effects on viral fitness114. The HVD is 
also involved in interaction with host cell proteins, resulting in the formation of distinct 
protein complexes in Old and New-World viruses115. These interactions include the 
cellular machinery responsible for the formation of stress granules, which alphaviruses 
utilize to their own replicative benefit116–119. These interactions are highly specific to viral 
species as well, and may partially drive the differences in pathogenesis seen between 
species119–121.  
Nonstructural protein 4 
NsP4 is produced in small amounts by most alphaviruses due to the inclusion of 
a stop codon between nsP3 and nsP455,57. Altering expression levels of nsP4, either to 
increase or decrease expression, decreases viral fitness, indicating that tight control of 
expression is highly important122. The tight limit on expression of nsP4 is also promoted 
by it being targeted by N-end rule degradation, further limiting the amount present in the 
cell123.  
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NsP4 is the RNA dependent RNA polymerase (RDRP) of the alphaviruses and is 
active in both positive and negative-sense RNA synthesis, with the specificity being 
determined by the cleavage state of the other nsPs61,85,124. NsP4 can display RNA 
synthesis activity alone, but the activity is enhanced by the presence of the other 
nsPs124–126.  
NsP4 also has a large N terminal region that lacks predicted structure or function. 
Our own work has predicted that this region is somehow involved in viral RNA synthesis, 
as mutations in this region result in resistance to the effects of a drug that inhibits the 
production of new viral RNA66,127. However, the function of this region remains unclear. 
Work by others has also shown that mutations in this regions have a broad range of 
effects on viral RNA synthesis128. This work, as well as the antiviral resistant VEEV 
isolates that have been recovered in our lab127 indicate that this region plays an 
important role in RNA synthesis of these viruses potentially in tandem with nsP2. This 
indicates that these proteins have additional, complex interactions and roles in viral 
biology that remain to be understood.  The functions of the nsPs are summarized in 
Table 1. 
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Protein Structures Functions 





caps viral RNA making it 
usable by ribosomes, 
anchors the replication 
machinery to cellular 
membranes75,85–87,89–92 
nsP2 helicase domain, ADP 
binding region, cysteine 
protease, methyl 
transferase like domain 
unwinds viral RNA for 
replication, cleaves the 
polyprotein into its 
constitutive parts, 










involved in host cell 
interactions85,106–
114,116,117,120,121,129
nsP4 RNA dependent RNA 
polymerase domain 
synthesizes new viral 
RNA57,61,85,122–126,128,130 
Table 1. Summary of alphavirus nonstructural protein functions 
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Current state of alphaviral therapy development 
Currently there are no approved therapeutics or vaccines for alphaviral disease. 
The development of treatments is urgently needed due the global range of alphaviruses 
and their continuous emergence into naive populations. This is compounded with the 
high risk of alphaviruses expanding their geographic ranges due to climate change. 
There have been many investigations into potential alphaviral therapeutics; however 
thus far, none have resulted in clinically approved treatments.  
Several studies have examined the efficacy of currently approved broad 
spectrum antiviral treatments. Ribavirin, a common standard of care in the treatment of 
viral infections, has been found to be ineffective131. Interferon α, another common 
antiviral treatment, has been found to be effective in mouse models at high doses, when 
it is pegylated to increase its halflife132. However, interferon treatment has severe side 
effects, and is particularly noted for the neurological symptoms it induces, such as 
depression133.  
A recently licensed drug of interest is the broadly anti-influenza treatment 
favipiravir. Created and initially tested in Japan, this is a nucleotide analogue which has 
been found to inhibit the polymerase of influenza viruses134. Treatment with favipiravir is 
mildly efficacious against WEEV, increasing survival in infected mice134,135. Also, 
treatment with this drug during the acute phase of infection resulted in clearance of 
CHIKV from infected mice, but there was no effect on the infection if treatment was 
initiated in the chronic phase136. It is important to note, that this treatment was not very 
efficient, requiring high doses of drug and delivery mechanisms that would be impractical 
during a natural outbreak of these viurses135,137 
29 
There have also been many other investigations into other potential treatments, 
such as therapeutic antibodies, mifiprestone analogues, and antimicrobial peptides138–
140. Promising data has come from treatment with antagonists of argonaut 2, an 
important protein in RNA silencing141 and inosine-5’-monophosphate (IMP) 
dehydrogenase, an enzyme involved in guanine synthesis142131143. Finally, there has 
even been work that has examined the effects of compounds like β-d-N4-
Hydroxycytidine, which increases the mutation rate during viral RNA synthesis in an 
attempt to induce damage in the genome144. However, as mentioned above, none of 
these leads have led to therapies licensed for the treatment of alphaviral infection in the 
clinic. Of particular interest in ongoing antiviral research is the development of viral 
targets that can be perturbed by treatment, leading to the development of more specific 
antiviral therapies with minimal side effects.  
The development of alphaviral therapies in the Chung lab 
The Chung lab has a history of antiviral drug development, and is known for the 
development of high throughput screening processes for the identification and 
characterization of novel therapeutic compounds127,145–147. Briefly, libraries of compounds 
are screened for increases in the viability of infected cells compared to a vehicle control. 
This is performed in a 384 well format allowing for rapid screening of thousands of 
compounds127. Compounds that meet the threshold for effectiveness are then assayed 
for antiviral effects as well as cytotoxicity, then promising compounds are further 
examined for pharmacological characteristics. This results in the identification of hit 
compounds which may become lead compounds themselves, or may be used to 
generate additional compounds using medicinal chemistry127.  
The antiviral drug discovery work using VEEV resulted in the discovery of an 
initial quinazolinone hit compound that was found to be highly effective against VEEV 
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with some efficacy against EEEV and WEEV as well127. Additional compounds that have 
unrelated mechanisms of action were also discovered using this same process, such as 
compound ML416, a pyrimidine analoge146. The initial quinazolinone compound was 
then further developed in collaboration with a medicinal chemist to the current lead 
compound ML33666,148. The hit compound was also used in several basic assays of 
compounds functionality and it was found to act primarily early in infection. This, 
combined with sequencing data from resistant viral isolates, indicated that the hit 
compound, and its derivative ML336 , were potentially acting to inhibit viral RNA 
synthesis in the infected cell148. The characterization of ML336 and its activity in the host 
cell will be discussed at length in the following chapter. A selection of compound 
structures that were used in this characterization work is included in chapter 2.  
The Chung lab not only tests these compounds as potential therapeutics, but 
also utilizes this expertise in antiviral drug discovery to probe viral biology. The antiviral 
compounds identified and developed in this process can be used as probes to produce 
mutant viruses that resist drug treatment148. These mutant isolates can then be 
sequenced and used to examine previously unknown biological activities of the viruses 
used. This process is described in detail in chapter 4 of this work. Where an anti-VEEV 
compound was used to probe the nonstructural proteins for novel biological functions.  
Objective of Dissertation 
Alphaviruses are important pathogens of both human and animal hosts and are 
of particular concern due their potential use in biological warfare. Several of these 
viruses are also rapidly expanding into naïve populations. There are currently no 
approved vaccines or antiviral strategies available for the treatment or prevention of 
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these viruses. New potential therapeutics need to be characterized and further 
developed. Our group has developed and begin to examine several anti-VEEV 
compounds and these require more complete study to determine their mechanism(s) of 
action127. Novel antiviral compounds also have the potential to be used as probes to 
characterize alphaviral biology. This is primarily carried out by the isolation and 
characterization of compound resistant viruses. Mutations in these viruses can be 
identified127 and any alterations in the behavior of these viruses can be mapped to the 
mutated region(s). These avenues of research were explored in the context of the 
following aims: 
1) To determine the mechanism of action of the anti-VEEV benzamidine
compound ML336.
2) To characterize the hypothetical interaction between amidine scaffold
compounds and the nonstructural proteins of VEEV.
3) To describe the biological function of the regions of nsP2 which were found to
be important to ML336 activity.
Justification 
Alphaviruses are important pathogens of both humans and domesticated 
animals, and the lack of therapeutic and preventative options means that there is a 
significant need for research to find and characterize new potential therapeutics and 
drug targets.  
The design of antiviral drugs has been historically rather difficult, as the 
pathogens utilize predominantly host systems for their biological processes. While there 
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has been some success with antiviral development recently, these drugs often have 
significant side effects making them poorly tolerated and underutilized149,150151152153.  
The current lack of anti-VEEV treatments, as well as the generally poor track 
record of many antiviral compounds, have led to our own interest in developing better 
antiviral compounds, with a focus on alphaviruses generally and VEEV specifically. This 
virus is not only a risk of natural infection, but is also a high-risk agent for misuse, 
making the development of treatments high importance.  
Further, there are many areas of alphaviral biology that remain poorly defined, 
despite extensive study. Antiviral compounds can be used to derive treatment resistant 
viruses. Those viruses that resist treatment can be sequenced for mutations in their 
genomes, and then these mutants characterized by classical virological methods. This 
method has the advantage of only discovering mutations that are compatible with 
replication, avoiding the creation of nonviable mutants which is common in random 
mutagenesis studies. With the characterization of these isolates, new information about 
the function of the viral proteins and their interaction with each other and cellular 
components can be gained.  
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CHAPTER 2 
BENZAMIDINE ML336 INHIBITS VEEV RNA SYNTHESIS 
Skidmore AM, Adcock RS, Jonsson CB, Golden JE, Chung DH. Benzamidine 
ML336 inhibits plus and minus strand RNA synthesis of Venezuelan equine 
encephalitis virus without affecting host RNA production. Antiviral Res. 2020 
Feb;174:104674. doi: 10.1016/j.antiviral.2019.104674. Epub 2019 Dec 6. PMID: 
31816348; PMCID: PMC6935354. 
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Overview 
Venezuelan equine encephalitis virus (VEEV) is an alphavirus that is endemic to 
the Americas. VEEV outbreaks occur periodically and cause encephalitis in both 
humans and equids. There are currently no therapeutics or vaccines for treatment of 
VEEV in humans. Our group has previously reported on the development of a 
benzamidine VEEV inhibitor, ML336, which shows potent antiviral activity in both in vitro 
and in vivo models of infection. In cell culture experiments, ML336 inhibits viral RNA 
synthesis when added 2-4 hours post-infection, and mutations conferring resistance to 
this activity occur within the viral nonstructural proteins (nsP2 and nsP4)127. This led us 
to hypothesize that ML336 targets the viral replicase complex and inhibits viral RNA 
synthesis. Using ML336 and structurally related compounds, we demonstrate that the 
cellular antiviral activity of this antiviral scaffold correlates with inhibition of viral RNA 
synthesis. However, ML336 has no effect on the RNA synthesis of the closely related 
CHIKV or on cellular RNA synthesis. With a combination of fluorography, strand-specific 
qRT-PCR, and tritium incorporation, we demonstrated that ML336 inhibits the synthesis 
of the positive-sense genomic, negative-sense template, and subgenomic RNAs of 
VEEV. In summary, ML336 and related compounds inhibit all stages of VEEV RNA 
synthesis during infection, and this activity mediates the antiviral effect of these 
compounds.. 
Introduction 
Venezuelan equine encephalitis virus (VEEV) is a single-stranded, positive-
sense, RNA virus belonging to the family Togaviridae, which includes other medically 
important mosquito-borne viruses such as Chikungunya virus (CHIKV), and Eastern and 
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Western equine encephalitis viruses (EEEV and WEEV respectively)7. The encephalitic 
alphaviruses, VEEV, WEEV, and EEEV, are closely related, sharing a recent common 
ancestor as determined by phylogenetic analysis154. VEEV generally causes a mild 
febrile disease, while approximately 1% of patients suffer from encephalitis, leading to 
death in about 10% of these encephalitic patients7. Only supportive care is available for 
those with VEEV infection.  
Encephalitic alphaviruses have caused periodic outbreaks in the Americas 
throughout the 20th century, and of these viruses VEEV has been the most significant 
public health burden. Historically, large VEEV outbreaks occur about every 15 - 20 
years, typically affecting thousands of equids and humans. For example, between 1962 
and 1972 in Central America15, over 109,000 human cases of VEEV were reported, with 
nearly 1,000 neurological cases and over 500 associated human fatalities. These 
outbreaks also caused a significant burden to the agricultural industry with over 800,000 
reported deaths of equids due to VEEV infection.  
In addition to large natural outbreaks, VEEV poses additional threats to the 
public. VEEV is classified as a Select Agent by both the Centers for Disease Control and 
Prevention and United State Department of Agriculture for its historic and potential use 
as a bioweapon22. There are currently no licensed treatments or vaccines for VEEV, or 
any other alphaviral infection in humans. Due to the stochastic nature of VEEV 
outbreaks, and difficulty in defining target groups for vaccination, therapeutics could be 
crucial for control of VEEV.  
A wide variety of compounds have been reported to show anti-VEEV activities. 
These include mifepristone analogues, argonaute-2 antagonists, therapeutic antibodies, 
compounds that induce mutations in the viral genome, and naturally expressed host 
antimicrobial peptides to name a few138–140,143,155. Efforts using the broad spectrum, FDA-
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approved antivirals interferon and ribavirin resulted in antiviral effects only at doses that 
were higher than are clinically relevant131,132. Other discovery efforts using nucleoside 
analogues or non-nucleoside analogues have shown moderate effects against 
VEEV146,156. Lastly, the broadly anti-influenza drug faviprivir134,136, shows efficacy against 
some alphaviruses135. However, this drug has not been tested against VEEV in a mouse 
model, and its efficacy against these related viruses is poor, requiring doses of up to 400 
mg/kg/day135,157 
To address the unmet need for VEEV therapeutics, we employed a high-
throughput, cell-based, anti-VEEV screen and discovered a novel quinazolinone hit 
compound (CID:15997213)158. This compound showed significant promise as a small 
molecule inhibitor of VEEV infection with an EC50 of 1.9 µM in a cell culture assay, and 
100% protection of VEEV-challenged mice at a dose 50 mg/kg in a lethal VEEV infection 
model127. This hit compound was then further refined using medicinal chemistry 
approaches in pursuit of compounds with superior pharmacological characteristics. The 
most promising of these further derived compounds was ML336, Figure 6 A.159. ML336 
shows potent and specific anti-VEEV (EC50 = 32 nM) activity in vitro, and VEEV titer 
reduction greater than 7.2 logs at 5 µM145,159. ML336 also effectively protected mice in a 
lethal VEEV infection model, with no apparent toxicity at any of the examined doses159.  
Our previous resistant mutation studies suggest the hit quinazolinone compound 
and benzamidine ML336 both inhibit VEEV replication by interfering with non-structural 
proteins 2 and 4 (nsP2 and nsP4) in the middle phase of replication127. NsP2 and nsP4 
are essential proteins of the viral replicase complex of alphaviruses7,102,124. The incoming 
viral genomic RNA (49S) is translated to form the polyprotein nsP123 and nsP4. The 
polyprotein then synthesizes negative-sense RNA using the genomic RNA as the 
template strand61,160, Figure 6 B. NsP123 rapidly undergoes cleavages mediated by the 
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protease activity of nsP258,59, resulting in nsP1, nsP23, and nsP4, and then further into 
nsP1, nsP2, nsP3, and nsP4 (nsP1/2/3/4). The mature replicase complex, nsP1/2/3/4, 
synthesizes the positive-sense, 49S viral genomic and 26S subgenomic RNAs61,103. This 
viral RNA synthesis by the mature replicase complex occurs in spherules, micro-
invaginations on intracellular organelles, in the infected cells91,161. RNA-dependent RNA 
polymerase (RdRP) activity is carried out by nsP4, and nsP2 also exhibits nucleoside 
triphosphatase (NTPase) activity and helicase activity during RNA synthesis, in addition 
to the aforementioned protease activity for processing of the polyprotein88,96,162. 
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Figure 6. Summary of VEEV replication A) The structure of the VEEV inhibitory amidine 
compound, ML336, as has been previously reported. B) A summary of the RNA 
replication process of alphaviruses. First, the genomic RNA (green line) is released from 
the virion into the cytoplasm, where it can recruit ribosomes and be translated into the 
initial polyprotein, nsP123/4. This short-lived, initial polyprotein then synthesizes 
negative-sense RNA template strands (yellow line) from the positive-sense genome. The 
polyprotein then undergoes self-cleavage to form the mature, stable, replicase complex, 
nsP1/2/3/4, which then synthesizes additional genomic RNA (49S) as well as 
subgenomic RNA (26S, blue line). 
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In order to characterize the potential of viral populations to gain resistance to 
these antiviral treatments, experiments were performed that isolated resistant virus from 
the treated population. The locations of mutations granting resistance were then 
determined using sequencing, which can provide information on both potential 
mechanisms of compound action as well as potential sites of interaction between viral 
proteins and the compounds. Resistance mutations to the hit quinazolinone compound 
and benzamidine ML336 both map to two regions; 1) the N-terminal region of nsP2, 
nsP2 mutations Y102C, D116N, E117V, E118V, and 2) the N-terminal region of nsP4, mutation Q210 
in nsP4Q210R58,85,88,96,127,130,162. The ML336 resistance mutations in nsP2 were clustered in 
a region that has recently been shown to be part of the so-called “stalk” domain of the 
helicase domain98. An X-ray crystal structure of CHIKV nsP2 helicase domain shows 
that the nsP2 Y102, D116, E117, and E118 residues are not associated with the active site or 
RNA recognition domains of the enzyme. Rather, these residues are within the distal 
part of a large alpha helix and flanked by smaller disordered regions. The resistance 
mutations in nsP4 are also upstream of the active site of the RdRP, in a region with no 
known functional activity125. Previous work in Sindbis virus indicates that the N-terminal 
region of nsP4 has importance for viral RNA synthesis possibly in a protein-to-protein 
interaction dependent manner; however, no clear functions have been understood163. 
In this study we sought to understand how ML336 and its benzamidine 
analogues inhibit VEEV replication with a hypothesis that ML336 is directly-acting on the 
replicase complex and interferes with viral RNA synthesis. Our results confirm that viral 
RNA synthesis is efficiently abrogated by ML336, an activity mediated through the viral 
replicase complex. We found that the synthesis of all species of viral RNAs (i.e., the 
genomic (49S), subgenomic (24S) positive-sense RNA, and negative sense RNA) are 
inhibited by ML336, and that the RNA inhibition displayed by ML336 is maintained in a 
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cell free system of viral RNA synthesis. These findings suggest that the primary antiviral 
activity of ML336 is the inhibition of viral RNA synthesis during infection. 
 
Materials and Methods 
Cell culture and viral strains 
 Baby hamster kidney (BHK) clone 21 cells (ATCC CCL-10) and Vero 76 (African 
Green monkey kidney fibroblasts) (ATCC® CRL-1587™) were maintained in Modified 
Eagle’s Medium with Earle’s Balanced Salt Solution and L-glutamine (MEM-E, Corning 
10-010-CV) supplemented with 10% fetal bovine serum (FBS) (Corning 35-011-CV). 
Cells were maintained at 37 C in humidified incubators with 5% CO2. VEEV strain TC-83 
(gift of Dr. Connie Schmaljohn, USAMRIID) was used for this study. The strain V3526 
was generated from a plasmid as described previously (Chung et al., 2014). Infections 
were carried out using a virus infection medium (Modified Eagle’s Medium with Earle’s 
Balanced Salt Solution supplemented (Corning 15-010-CV) with 1x GlutaMAX (Gibco 
35050061), 25 mM HEPES (Corning 25-060-Cl), and 10% FBS. For Chikungunya virus 
(CHIKV) experiments, CHIKV strain 181/25 (BEI Resources NR-13222) was used. 
V3526 experiments were carried out in an infection media that contained L-glutamine 
instead of GlutaMAX (Modified Eagle’s Medium with Earle’s Balanced Salt Solution with 
L-glutamine (Corning 10-010-CV), 25 mM HEPES, 10% FBS) 
Immunoblot analysis  
 Cells were lysed using Laemmli buffer 4% SDS (RPI L22010) w/v, 20% glycerol 
w/v, 120 mM Tris-HCl pH=6.8, bromophenol blue) and 42 µM of dithiothreitol (DTT Enzo: 
ALX-280-001-G025)) and the homogenate was passed through a needle to shear the 
DNA, with additional sonication as necessary. After denaturation at 100C for ten 
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minutes, samples were loaded onto a gradient gel (4-20%, GenScript, M42012) and run 
at 140 V for 90 minutes in 1X MOPS-SDS buffer (GenScript, M00138). Proteins were 
transferred to a PVDF membrane (Bio-Rad 1620177). The membrane was blocked with 
5% dry milk in TBS-T, and probed using antibodies for the indicated proteins. Anti-nsP2 
(Clone no. 8A4B3, available from Kerafast, EUL015) was generated as a custom mouse 
monoclonal antibody from GenScript using bacterially expressed recombinant nsP2 
protein, used at a final concentration of 0.4 µg/mL. Beta-actin was detected using an 
antibody directly linked to horse radish peroxidase (HRP) (Cell Signal 8H10D10) at a 
dilution of 1:1,000. Anti-nsP2 was detected using (HRP)-conjugated rabbit anti-mouse 
IgG antibody (Sigma A0168) final concentration 1:10,000. Images were developed using 
ECL reagent and captured using an Azure Biosystems c300 imaging system.  
Analysis of viral RNA synthesis in vivo by metabolic labelling with 3H-uridine 
Cells were infected with VEEV at a multiplicity of infection (MOI) of ten on ice for 
one hour; and afterwards, cells were washed with ice-cold 1X phosphate buffered saline 
(PBS Caisson Labs PBL07) and transferred to a 37C CO2 incubator to initiate the 
replication (T=0). At 6 hours post-infection (HPI), cells were washed and pulsed with 
virus infection media containing actinomycin D (act D) (1 µg/mL, Sigma Aldrich A9415), 
tritium-labelled uridine (3HU) (5 µCi/mL, Perkin Elmer NET367250), and ML336 at 
various concentration for two hours. Total RNA was isolated from the cells using RNAzol 
RT according to manufacturer’s instructions (Molecular Research Center RN190). Total 
RNA was mixed with 10 mL liquid scintillation cocktail (BETA BLEND, MP Biochemicals 
0188245004) and the radioactivity was measured using a Perking Elmer Tri-Carb 2910 
TR liquid scintillation counter. For CHIKV, infection proceeded to 8 HPI for 3HU pulse 
labelling. For compound treatment, ML336 dissolved in DMSO (Sigma Aldrich D8418) 
was added in the 3HU labelling mixture with a final DMSO concentration of 0.25%. 
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ML336 concentrations are indicated in the results section for specific experiments. For 
cycloheximide (CHX) (Sigma Aldrich C7698) treatment, cells were treated with 3HU 
labelling mixture containing CHX with a final concentration of 8.8 µg/mL.  
Fluorography 
250,000 cells were infected at an MOI of 20 with VEEV TC-83. Cells were pulsed 
for the indicated times post infection with 1 µg/mL act D, 40 µCi/mL 3HU and 2.5 µM 
ML336. RNA was isolated using RNAzol RT. One µg RNA was used per treatment for 
the fluorgram. Fluorography was performed following a protocol published by John 
Aris164. 
RNA labeling of V3526 and mutant viruses 
Cells were infected with VEEV V3526 at an MOI of 5 and pulsed in 2 hour 
increments up to 14 hours. Later time points were also collected at 18, 24, 30, and 40 
HPI. Peak RNA synthesis was found to occur between 14 and 18 HPI (data not shown). 
To compare the effectiveness of the compound, cells were infected at an MOI of 3 and 
allowed to proceed to 13 HPI before pulsing with 1 µM ML336 or an equivalent volume 
of DMSO. RNA was collected and radioactivity was detected as described above.  
Strand-specific quantitative real-time PCR (qRT-PCR) of VEEV RNA 
Detection of positive and negative sense, genomic viral RNA was carried out 
using a strand-specific qRT-PCR method adapted from Plaskon et al165. Briefly, cDNA 
was generated using tagged primers for detecting positive-sense and negative-sense 
RNA. The generated cDNA was then used in qRT-PCR using TaqMan chemistry 
(Applied Biosystems TaqMan gene expression master mix ThermoFisher 4369016) with 
a strand-specific primer set. A fluorescent probe was used for both analyses. The primer 
sequences are given in the following table. Lowercase sequences are additional 
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sequence added for primer identification, sequences in italics are specific for viral RNA, 
and sequences in bold were used to identify only those cDNA sequences that were 










aataaatcataa CTG ACC TGG AAA CTG AGA CTA TG 
nsP1 positive 
REV 
aataaatcataa GGC AGT ATC GTG AAT TCG ATG C 
nsP1 negative 
FWD 
aataaatcataa GGC GAC TCT AAC TCC CTT ATT G 
nsP1 negative 
REV 
aataaatcataa GGC AGT ATC GTG AAT TCG ATG C 
nsP1 probe /56-FAM/TCC GTC AAC /ZEN/CGC GTA TAC ATC CTG /3IABkFQ 
Enrichment of viral replicase complexes from infected cells 
 VEEV replicase complexes were isolated according to the protocol published by 
Barton et al166. Cells were infected with VEEV TC-83 at 10 MOI and incubated for 6 
hours. Then, cells were washed with ice-cold, sterile PBS and the cells were incubated 
in hypotonic RS buffer (10 mM NaCl, 10 mM Tris-HCl, pH7.8) supplemented with 
Protease inhibitor cocktail III, 30µL per 20x106 cells, (Research Products International 
P50700-1) on ice for 15 minutes. Cells were scraped into buffer and thoroughly 
homogenized using a Dounce homogenizer. Nuclei were removed by centrifugation at 
900 x g for 10 minutes at 4 °C. Supernatant containing the cytoplasmic fraction was 
transferred to microcentrifuge tubes and centrifuged at 15,000 x g for 20 minutes at 4 °C. 
The supernatant (S15 fraction) was removed and pellets (P15 fraction) were suspended 
in RS buffer supplemented to 15% glycerol for storage at -80 °C.  
In vitro viral RNA synthesis assay 
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VEEV viral RNA synthesis assay was adapted from Barton et al166. Ten 
microliters of P15 fraction enriched for VEEV viral replicase complexes, which is 
equivalent of approximately 1.25 x 106 infected cells, was combined with a same volume 
of a RNA synthesis mix (100 mM Tris-HCl pH 7.8, 100 mM KCl, 20 µg/mL act D, 20 mM 
DTT, 10 mM creatine phosphate, 50 µg/reaction creatine phosphokinase, 4 mM of ATP, 
GTP, and UTP, 20 µM CTP, 12 mM MgCl2) (nucleotides from NEB N0450S) on ice and 1 
µL of SUPERaseIn RNase inhibitor (Ambion AM2694 ), 5 µg of yeast tRNA (Ambion 
15401011), and 5 µCi of [α-33P]-CTP (Perkin-Elmer NEG608H) were added per reaction. 
After an incubation at 37 °C for 90 minutes, RNA was isolated from each reaction using 
RNAzol RT and RNA mini prep kit columns (Zymo Research R2052) according to 
manufacturer’s instructions, with an additional wash step before elution. For compound 
addition, ML336 was added to reaction mixtures before incubation at 37 °C at the 
indicated concentrations. The final DMSO concentration was 0.25%. 
Autoradiography of viral RNA 
After extraction of viral RNA from the in vitro reactions, the RNA was mixed 1:1 
with a glyoxal loading buffer/dye with ethidium bromide (Ambion AM8551) and denatured 
at 50 °C for 30 minutes. Samples were chilled briefly and loaded for RNA 
electrophoresis. RNA electrophoresis was performed through a denaturing agarose gel 
containing 0.8% agarose, 1X MOPS (Quality Biological 351-059-10), and 2.2 M 
formaldehyde. Electrophoresis was performed at 60 V for 70 minutes, then the gels were 
rinsed in nuclease-free water once and treated with 0.1N NaOH for 40 minutes at room 
temperature with continuous rocking. Gels were neutralized in 20X saline-sodium citrate 
(SSC) buffer (3 M NaCl, 300 mM trisodium citrate, pH7.0) for 40 minutes. RNA was 
transferred to a neutral nylon membrane (GE Nytran 10416296). The RNA on the 
membrane was then UV cross-linked for 5 minutes at 4 mW/cm2. Autoradiograms were 
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developed using a phosphor screen (Kodak K screen 1707843) and documented using a 
Pharos FX plus (BioRad). Densitometry analysis was performed using Fiji image 
analysis software167. 
Cell-based anti-VEEV assay 
Anti-VEEV activity of compounds was measured using a cell-based CPE assay 
as previously described158. Briefly, Vero 76 cells seeded in a 96 well plate were infected 
with VEEV TC-83 at an MOI of 0.05 in the presence of test compounds, highest 
concentration of 50 µM, serially diluted 1:2 with a total of eight concentrations, lowest 
concentration 400 nM. Infected cells were incubated for 48 h and cell viability, protection 
from VEEV-induced CPE, was measured using CellTiter-Glo (Promega G7570). EC50 
was calculated with a 4-parameter logistic model (XLfit, IBDS). 
Statistics 
Statistics were performed in GraphPad Prism version 9. Unless otherwise 
indicated significance was calculated using ANOVA with Dunnett corrections for multiple 
comparisons. All graphs use the mean value, with error reported as standard deviation. 
Results 
VEEV viral RNA production peaks at 6-8 hours post infection. 
 To determine the optimal timepoint to examine the inhibitory effects of ML336 on 
viral RNA synthesis, we first measured the rate of VEEV viral RNA synthesis over the 
course of infection using metabolic labeling of RNA. After BHK21 cells were infected with 
VEEV TC-83 at an MOI of 10, the synthesis of viral RNA was tracked in two-hour 
increments beginning at 2 HPI by pulsing with 3HU in the presence of act D, which 
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allowed us to detect only the synthesis of viral RNA by inhibiting cellular RNA 
transcription from DNA templates. Using this assay, we found that VEEV RNA synthesis 
was detectable at 2 HPI, and continued until 18 HPI Figure 7 A. VEEV RNA synthesis 
reached its peak between 6 and 8 HPI and began to decrease at 10 HPI. There is no 
significant difference between the three pulses from 4-10 HPI. So any of the three pulses 
should allow for strong detection of viral RNA synthesis. The 6-8 HPI pulse was selected 
due to a balance of length of the experiment, as well as the higher magnitude displayed 
in this assay. 
We measured expression of nsP2 as a marker for the viral replicase complex 
over the course of infection by immunoblotting. Detectable amounts of nsP2 were 
detected at 4 HPI, and the expression peaked at 8 HPI, which is consistent with the 
timeline of viral RNA synthesis Figure 7 B. Later time points were selected due to 
previous knowledge about the kinetics of nsP2 in our lab. These data together indicate 
that the greatest level of RNA synthesis of VEEV is from 6-8 HPI. Based on this result, 






Figure 7. VEEV RNA synthesis peaks at 6-8 HPI.  
A) BHK 21 cells were infected with VEEV as described in the Materials and Methods of 
this chapter and treated with act D and 3HU to selectively label newly synthesized viral 
RNA. Total RNA was isolated and subjected to liquid scintillation counting. The amount 
of label detected is reported as counts per minute (CPM) per microgram of isolated 
RNA. NC is an uninfected negative control collected at 18 hours. Bars represent two 
biological replicates from one representative experiment of two. Error bars indicate 
standard deviation. B) BHK 21 cells were infected with VEEV and total cell lysate was 
used for immunoblotting to detect nsP2. Beta-actin is included as a protein loading 
control. Image is from one representative experiment of three. 
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Antiviral activities of ML336 and derivatives correlated with their inhibition of viral 
RNA synthesis.  
Based on our previous findings127, we hypothesized that the primary antiviral 
mechanism of the benzamidine scaffold, including ML336, is inhibition of viral RNA 
synthesis. To test this hypothesis, we chose to examine the RNA synthesis inhibition 
activities of an array of structurally analogous compounds (Table 1) based around the 
ML336 amidine scaffold Figure 8159. Multiple compounds have been developed using the 
base structure of ML336, with the pursuit of further improvements to both efficacy and 
pharmacokinetics, this optimization is pursued for every potential lead therapeutic 
compound that is discovered through the high throughput screening process. Each of 
these compounds has been found to be variously effective at inhibiting VEEV induced 
CPE. If the efficacy of this range of compounds at inhibiting VEEV induced CPE and 
RNA synthesis corelate, it indicates that RNA synthesis inhibition is a feature of the more 
general benzamidine scaffold and not unique to ML336. This also strengthens the 
hypothesis that RNA synthesis inhibition is a major contributor to the antiviral activity of 
the benzamidine compound family. ML416, which has an antiviral mechanism that is 
independent of viral RNA synthesis and is structurally distinct, was used as a control for 
comparison146. We also included our initial hit compound from our high throughput study, 
CID15997213127. 
Nine compounds with 50% cytopathic effect (CPE) inhibitory concentrations 
(EC50-CPE) ranging from 0.1 μM to greater than 50 μM were tested in the 3HU labeling 
assay159. Cells infected with VEEV TC-83 at an MOI of 10 were treated with each 
compound at 1 µM at six HPI and their RNA synthesis inhibitory activities were 
compared with their EC50-CPE. The concentration was held constant instead for example 
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using the IC50 of each compound so that each compounds efficacy could be directly 
compared. Using the middle efficacious concentration of each compounds would not 
allow for variation between the measurements, and the correlation could not be 
determined. Each activity was quantified as percent inhibition compared to the DMSO-
treated control. While ML416 did not show any RNA synthesis inhibitory activity as 
expected, each of the compounds showed various amounts of reduction of viral RNA 
synthesis Figure 8. Importantly, we found a trend that compounds that were more potent 
in the CPE-bases assay were generally more efficacious as inhibiting RNA synthesis, 
R2= 0.42 p=0.059, as measured by the incorporation of 3H-uridine into viral RNA. This 
experiment was performed from 6-8 HPI as this was found to be the time of maximal 
RNA synthesis by the virus. At this time post infection, and at the MOI that was used, the 
virus has already entered the cell and performed the activities of early infection (i.e. 
receptor binding, endocytosis, release of the viral RNA into the cytoplasm) and the initial 
translation and processing of the nsP polyprotein. Thus, the reduction in viral RNA 
synthesis that is seen to occur after treatment with these compounds is likely to occur 
independently from these other early infection processes. This indicates that the anti-
RNA synthesis activity of the benzamidine family is likely mediating the antiviral effects 
that that occur during infection with VEEV. 
Several compounds that were tested in the assay were strongly inhibitory of RNA 
synthesis but had little effect on cell viability, such as CMP3. While none of these 
compounds were cytotoxic, CC50 > 50 µM159, it is possible there are some off target 
effects that make the compounds less protective.  
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Figure 8. Compounds derived from ML336 also inhibit viral RNA replication. 
BHK 21 cells were infected with VEEV as described and infection proceeded to 6 HPI. 
Cells were pulsed for 2 hours with actD, 3HU, and one of the compounds of interest at 1 
µM or DMSO vehicle control. The amount of 3HU incorporated into the viral RNA was 
quantified by liquid scintillation counting. The percentage of label that was incorporated 
compared to a DMSO control, with 100% inclusion resulting in 0% inhibition, and 0% 
inclusion resulting in 100% inhibition. This data was compared to the percent protection 
from TC-83-induced CPE in a cell-based assay. Percent protection is the percent of 
viable cells after infection compared to DMSO vehicle control treatment. R2=0.42 
p=0.059, calculated using linear regression in GraphPad Prism. ML416 was included as 
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an outgroup, as it is effective at inhibiting VEEV induced CPE but is known to function by 
an RNA synthesis independent mechanism. Each point represents three biological 
replicates and the experiment was repeated twice (Exp 1 and Exp2). Compound IDs are 















CMP1 CB10002593 5.2 42.5 10.7 
CMP2 CB10002582 11.3 68.0 59.7 
CMP3 CB10002510 21.0 84.3 97.8 
CMP4 CB10002491 51.9 80.4 82.0 
Hit CB10000905 61.2 90.0 91.9 
CMP6 CB10002462 65.3 94.9 87.9 
CMP7 CB10002594 73.9 101.6 99.2 
ML416 CB10002681 95.1 -20.0 
CMP9 CB10002704 96.5 110.4 102.6 
ML336 CB10002700 106.6 112.7 103.0 
Table 2. Chemical IDs and effectiveness in the CPE and RNA inhibition assays. 
Compound ID numbers are the same as the structure IDs available in PubChem. 
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Table 3: Structures of the selected compounds 
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The anti-RNA synthesis activity of ML336 is VEEV-specific and has no effect on 
cellular RNA synthesis.  
Having determined that ML336 and related compounds are able to inhibit VEEV 
RNA synthesis during active replication, we sought to further characterize this anti-RNA 
synthesis activity. First, we determined the potency of ML336 against VEEV viral RNA 
synthesis. Cells were infected with VEEV strain TC-83 and treated with 3HU and various 
concentrations of ML336 from six to eight HPI as described in the Materials and 
Methods. The amount of 3HU incorporated into the total isolated RNA was measured 
and a dose response curve was generated to calculate the IC50 Figure 9 A. ML336 
showed strong, dose-dependent inhibition of viral RNA synthesis activity with an IC50 of 
1.1 nM with a standard deviation of 0.7 nM. At 40 nM, ML336 decreased viral RNA 
synthesis to 7% of the control. These data indicate that VEEV RNA synthesis is 
efficiently inhibited by ML336. Also, ML336 was efficacious at inhibiting viral RNA 
synthesis at the EC50 determined by the cell-based assay. 
Previously, we determined that compounds based around the ML336 
benzamidine scaffold had no antiviral effect on CHIKV in cell culture using the CPE 
assay145. If the antiviral effect of this compound is mediated by the inhibition of viral RNA 
synthesis, then CHIKV will also resist this activity. We measured the inhibition of RNA 
synthesis by ML336 treatment on CHIKV using the 3HU assay. As can be seen in Figure 
9 B, ML336 had no effect on CHIKV RNA synthesis even at 4 µM (P > 0.22, ANOVA), 
the highest concentration we tested, and 4000-fold higher than the IC50 value of the 
compound against VEEV in this assay, compared to an untreated positive control.  
To measure the effect of ML336 on cellular RNA production, uninfected BHK 
cells were incubated with ML336 at the indicated concentrations or with a DMSO control 
in the presence of 3HU without act D Figure 9 C. Overall, ML336 did not show an 
56 
inhibitory effect on cellular RNA synthesis. A small decrease in cellular RNA synthesis 
was detected only at the highest concentrations of ML336, 50 µM and 25 μM, which are 
over 20,000-fold higher than the IC50 value, indicating that the inhibitory activity of 
ML336 against cellular RNA synthesis is negligible at working concentrations.  
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Figure 9. The RNA synthesis inhibition of ML336 is highly specific and has no effect on 
cellular RNA synthesis.  
A) BHK 21 cells were infected with VEEV as described and cells were pulsed from 6-8
hours post infection with act D, 3HU, and ML336 at the indicated concentrations. Each 
point represents three biological replicates, error was calculated as the standard 
deviation. Dose-response curves were generated using four parameter curve fitting in 
Graph Pad Prism software 9th edition. B) BHK 21 cells were infected with CHIKV at an 
MOI of 10 and infection proceeded as for VEEV. Cells were treated with the indicated 
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amounts of ML336. U is an uninfected control. Graph is of one representative 
experiment of two total experiments, each point represents three biological replicates, 
and error is standard deviation. C) Uninfected BHK 21 cells were treated with VEEV at 
the indicated concentrations or DMSO control. Cells were pulsed for 2 hours with 
compound and 3HU. NL is an unlabeled control reaction. Graph is of a single 
representative experiment of two experiments, points each represent three biological 
replicates, and error is standard deviation.  
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Viral isolates that can replicate in the presence of ML336 resist the RNA synthesis 
of inhibition of the compound. 
 As previously mentioned, we have isolated several strains of VEEV that resist 
treatment by either our initial hit compound127 or ML336, by serially passaging in the 
presence of the compound or by direct sequencing in the presence of the compound. 
These resistant viruses have mutations mapped in the N-terminal regions of nsP2 (e.g., 
nsP2Y102C mutation) or of nsP4 (e.g., nsP4Q210K mutation)127. Either of these mutations is 
enough to cause resistance in isolation, i.e. only one of the two mutations is required for 
compound resistance. We hypothesized that if inhibition of viral RNA synthesis is the 
primary outcome of ML336 treatment, then these mutants would maintain levels of RNA 
synthesis similar to the parental virus in the 3HU incorporation assay. We introduced the 
mutations that were found in the mutant strains into the plasmid encoding the full, 
infectious genome of V3526 and then produced the mutant virus strains in the presence 
of the initial hit compound at a concentration of 5 µM127. After determining that maximum 
levels of RNA synthesis occurred at 14 HPI (data not shown) we performed a metabolic 
labeling experiment in the same manner as described in our methods.  
As expected, viral RNA synthesis of the parental V3526 was sensitive to 
treatment with ML336, and viral RNA synthesis was fully abrogated at 5 µM Figure 10. 
Comparatively, the mutant viruses showed varying levels of sensitivity to ML336. The 
nsP2Y102C mutant showed 76.2 % RNA synthesis compared to the control and nsP4Q210K 
mutant showed no inhibition compared to a vehicle control. This result clearly shows that 
the compound-resistant mutant viruses are able to overcome the RNA synthesis 
inhibitory effects of ML336. Our data so far support the hypothesis that ML336 is a viral 
RNA synthesis inhibitor that acts through nsP2 and nsP4. 
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Figure 10. ML336 resistant mutations grant resistance to RNA synthesis inhibition. 
Mutations were introduced to the clonal VEEV V3526 backbone and these mutant 
viruses were subjected to the RNA synthesis inhibition assay as described at a 
concentration of 5 µM ML336. The amount of 3HU label was quantified by liquid 
scintillation counting. The amount of incorporated label was divided by the amount 
present in the DMSO treated control and multiplied by 100 to yield the percent of RNA 
synthesis. Graph is from data from two experiments, each with three biological 
replicates. Error is reported as standard deviation. 
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ML336 inhibits both positive and negative RNA synthesis of VEEV. 
 During infection with VEEV, several RNA species are generated by the virus 
which have distinct functions. We next sought to determine if ML336 specifically targeted 
the synthesis of one or more of these RNA species. To determine if ML336 inhibits either 
positive or negative-sense RNA production, we used a strand-specific qRT-PCR165. 
VEEV-infected cells were treated either with ML336 or DMSO at 4 HPI, and the copy 
numbers of positive and negative-sense viral RNA were quantified and compared. This 
earlier time point was selected as the rate of negative-sense RNA production decreases 
later in infection. As shown in Figure 11 A, the control group (DMSO-treated) had almost 
a 1 log increase in the amount of positive-sense RNA and an approximately half log 
increase of negative-sense RNA during the period of 4 to 6 HPI. 
In the presence of ML336, however, the amount of positive- and negative-sense 
viral RNA did not increase at all, which demonstrated the inhibition of both positive- and 
negative-sense viral RNA synthesis by ML336. The presence of ML336 did not affect the 
ratio of positive to negative-sense RNA. The copy number of positive-sense RNA was 
10,000-fold higher than that of the negative-sense RNA at all time points and in both 
ML336 treated and untreated conditions. This difference in the levels of the RNA species 
is consistent with findings previously reported in alphaviruses by others168. These results 
show that the synthesis of both the positive and negative-sense strands of VEEV RNA 
was affected by ML336.  
ML336 inhibits the RNA synthesis by the mature replicase complex. 
 For alphaviruses, the majority of viral RNA synthesized in the infected cells is 
positive-sense RNA (See Figure 11 A) and the synthesis of positive-sense RNA is 
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dependent on the amount of negative-sense genomic RNA (Figure 5)85; therefore, the 
inhibition of negative-sense RNA synthesis would result in the inhibition of positive-
sense RNA synthesis . To determine if the inhibition of viral positive-sense RNA 
synthesis by ML336 is due to the inhibition of negative-sense RNA synthesis, we sought 
to test the effect of ML336 on positive-sense viral RNA synthesis alone. 
The alphavirus negative-sense RNA is produced only by the newly translated, 
short-lived, polyprotein, nsP123/4 or nsP1/23/461,160. Therefore, it has been well-
established that inhibition of translation (e.g., treatment with cyclohexamide) prevents 
the production of the negative-sense RNA by nsP123/4, which allows us to measure the 
positive-sense specific RNA synthesis by the pre-formed, mature, viral replicase 
complex85,169.  
We measured viral positive-sense RNA synthesis using our 3HU labelling assay 
in the presence of cyclohexamide (CHX), a translation inhibitor, and evaluated the effect 
of ML336, Figure 11 B. Treatment with CHX showed no significant difference in the total 
viral RNA production compared to the vehicle control. This data indicates that the 
majority of viral RNA that was being synthesized at this time was positive-sense RNA, 
which is consistent with data reported by others85 as well as our real-time PCR 
experiments shown in Figure 11 A. Importantly, we found that the treatment of VEEV-
infected cells with ML336 completely abrogated viral RNA production even in the 
presence of CHX. This shows that ML336 inhibited the synthesis of viral RNA generated 
by the mature replicase complex (i.e., positive-sense RNA), and the inhibition of the 
negative-sense viral RNA synthesis is not required for ML336 to inhibit positive-sense 




ML336 inhibits the synthesis of both genomic and subgenomic VEEV RNA.  
Having determined that ML336 inhibits the synthesis of positive-sense VEEV 
RNA, we sought to determine if the inhibition of the positive-sense RNA strand was 
specific to either the genomic or the subgenomic RNA. Alphaviruses synthesize two 
species of positive-sense RNAs, the genomic RNA (49S), which is packaged into 
progeny virions and is used for translation of the nonstructural polyprotein, and the 
subgenomic RNA (26S), which is responsible for the production of the structural genes. 
The expression of these two RNAs is controlled by the amount of polyprotein that has 
been synthesized, and the current cleavage state of the polyprotein61,103,160.  
To understand whether the inhibition of viral RNA synthesis was specific to 
genomic (49S) or subgenomic (26S) viral RNA, we analyzed the viral RNAs that were 
produced in the presence or absence of ML336 using fluorography of 3HU-labeled viral 
RNA. As Figure 11 C shows, the addition of ML336 to VEEV-infected cells at any time 
post-infection up to 8 hours completely abrogated synthesis of both genomic and 
subgenomic viral RNA. This indicates that addition of ML336 inhibits the synthesis of 
both 49S and 26S viral RNA in cells.  
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Figure 11. ML336 inhibits all stages of VEEV RNA synthesis. 
A) Strand-specific qRT-PCR was performed on RNA isolated from TC-83 infected BHK
21 cells that were either treated with ML336 at 5 µM or DMSO vehicle control. RNA copy 
number was measured by using a standard curve with known viral RNA copy numbers. 
Each point represents a mean and standard deviation from three biological replicates. B) 
Metabolic labeling of VEEV RNA was performed as before using act D and 3HU, with 
data collected by liquid scintillation counting. Cells were labeled from 6-8 HPI. CHX: 
cyclohexamide. Graph is from one representative experiments with three biological 
replicates per treatment. Error is reported as standard deviation. C) A representative 
fluorogram after treatment with ML336. Cells were treated with ML336 at 2.5 µM or 
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DMSO at the time points indicated and then the RNA was visualized by treatment with a 
scintillant and exposure to X-ray film as described in the materials and methods. 1 µg of 
RNA was used per lane. G: genomic RNA, SG: subgenomic RNA.  
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ML336 inhibits VEEV RNA synthesis in a cell-free system. 
The work outlined here implies that ML336 and related compounds function to 
inhibit VEEV infection by interfering with the synthesis of viral RNA. And this activity is 
specific to viral RNA and has minimal effect on cellular RNA synthesis (Figure 10). 
Further, it is known that the replication of viral RNA is carried out directly by the virally 
derived replicase complex58–61. This catalytic activity is also maintained by purified 
protein124,125 Additionally it has been previously found that viral isolates that resist 
treatment with these antiviral compounds have mutations in the N terminal region of 
nsP2 and nsP4148. When taken altogether, this led to our hypothesis that ML336 and 
related compound were likely to be directly interacting with the viral nsPs to mediate 
their anti-VEEV activities. Currently there has been no successful expression of the full 
length nsP2 protein of any alphaviruses, and the other nsPs are also known to be 
difficult to ectopically. This limited our abilities to examine a potential interaction between 
these proteins and ML336. This led to our use of a so-called cell-free RNA synthesis 
assay. 
The cell-free RNA synthesis assay was developed for alphaviruses many years 
ago and uses fractioned cellular components as both enzyme and template to generate 
viral RNA in the absence of complete, living cells166170. While this method does not 
completely remove cellular components from the assay, it greatly limits the amount of 
cellular proteins present, and is currently the best that can be done to isolate and 
examine the activities of the nsPs directly. The use of the P15, or membranous fraction, 
provides both template and polymerase to examine viral RNA synthesis. P15 fraction 
isolated from VEEV-infected cells was incubated with ribonucleotide substrates (e.g., 
ATP, GTP, and UTP) and radioactive CTP in the presence of ML336 or DMSO, then the 
in vitro synthesized viral RNA was analyzed on denatured agarose gels. 
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As shown in Figure 12 A, while there was no radiolabeled RNA produced by the 
P15 fraction of uninfected cells, three distinct viral RNA bands corresponding to genomic 
(49S), subgenomic (26S), and a replication intermediate, which has been previously 
reported on denaturing gels 166, were present in the RNA produced with P15 from virus-
infected cells. The addition of ML336 in the reaction decreased the amount of all three 
RNA species in a dose-dependent manner. At ML336 concentrations greater than 200 
nM, there was complete abrogation of all viral RNA synthesis. This result, complete 
inhibition of viral RNA synthesis of the P15 fraction, indicated that the inhibition of viral 
RNA synthesis by ML336 is independent from cellular metabolism and supported our 
hypothesis that ML336 inhibits viral RNA synthesis by a direct interaction with the viral 
replicase complex. 
 The IC50 value in this assay was then determined via optical density analysis 
from three separate experiments, and was found to be 49 nM, which is similar to the 
EC50 value as determined in our initial cell-based assays, Figure 12 B. This IC50 value is 
higher than that seen for RNA inhibition in our 3HU incorporation assay, Figure 9 A. This 
is most likely due to differences in the RNA labeling reactions. The 3HU incorporation 
assay labels all of the viral RNA that is being produced in the cell. However the cell-free 
synthesis assay is labeling primarily positive-sense RNA manufactured by mature 
replicase complexes. This could lead to less sensitivity as ML336 also inhibits the 
synthesis of negative-sense RNA.  
The autoradiogram in Figure 12 A and also shows a large amount of small RNA 
products being labeled that were not present in the fluorgram in Figure 11 C. This is due 
to the being different ways of making and labeling RNA. The fluorgram uses total 
isolated RNA from infected cells, which is made in an ideal system for the virus. The 
labeling periods are also rather long allowing for highly efficient incorporation of label 
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into the RNA. The autoradiogram, by contrast, is in a limited system, with minimal 
resources for the replicase complex. This minimal system is probably the cause of the 
increase in labeled small transcripts. These transcripts could be early terminated RNA, 
RNA synthesis initiating incorrectly, or RNA in the middle of synthesis 
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Figure 12. ML336 is active in a cell-free system. 
The P15 was isolated from BHK 21 cells infected at an MOI of 10 with VEEV TC-83. 
This material was combined with various reagents as described in the methods, with 
[α33P]-CTP to label viral RNA. A) A representative RNA gel showing the results of the 
labeling reaction. The 28S and 18S ribosome subunit rRNA were used as size markers. 
RI: a VEEV replication intermediate; G: the VEEV genomic RNA; SG: the VEEV 
subgenomic RNA. U is an uninfected control. 0 µM is a DMSO treated control. RNA 
amounts were controlled by using equal numbers of infected cells (1.25 x 106) per 
reaction, and total isolated RNA was used from each reaction. B) Densitometry was 
performed on three images from separate experiments to quantify the amount of labeled 
RNA present. These results are shown as a dose response curve. The IC50 value in this 
assay was found to be 49 nM. 
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Discussion 
ML336 and its analogues have been discovered through medicinal chemistry 
efforts originating from a quinazolinone hit compound that was identified from a cell-
based high-throughput assay using live virus127. While our previous approaches using 
cell-based assays and mapping of resistance mutations strongly suggested viral RNA 
synthesis as the target step of this antiviral activity, the mechanism of action of the 
compounds has remained unclear127,145. In this study we employed additional cell-based 
and biochemical assays to evaluate the effect of these compounds on VEEV viral RNA 
and host cell synthesis. Our data suggest that ML336 and related compounds inhibit 
VEEV by directly preventing viral RNA synthesis via a direct interaction with the viral 
replicase complex. ML336 demonstrated an efficacious inhibitory activity in both cell-
based and cell-free viral RNA synthesis assays, and showed strong inhibitory activity 
against the synthesis of all viral RNA species. Our data strongly support the conclusion 
that the primary anti-VEEV mechanism of the amidine compound, ML336, is interfering 
with viral RNA synthesis.  
The inhibition of viral RNA synthesis mediated by interaction with the replicase 
complex has not yet been described for any antiviral with efficacy against alphaviruses. 
With regards to the molecular mechanism of these compounds, resistant mutations in 
nsP2 (e.g., nsP2Y102C) indicate that this region of nsP2 may be important for sensitivity to 
ML336. A homology model of VEEV nsP2 made using a recently published crystal 
structure of the N terminal region of nsP2 of CHIKV with the I-TASSER protein modeling 
server171–173, Figure 14, has shown that the residues that are important for sensitivity to 
ML336 are located in an accessory domain to the helicase, termed the stalk domain, in 
nsP298. The stalk domain is a large alpha helix that is external to the active site of the 
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helicase, which may imply that this region could be involved in the protein interactions in 
the replicase complex during infection.  
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Figure 13. Homology model of VEEV nsP2 N terminal region. 
A ribbon structure homology model of the first 465 amino acids of VEEV nsP2 was 
produced using I-TASSER. This model was made possible by the recent publication of 
the crystal structure of this same protein region from CHIKV by the Luo lab98 which was 
used as the basis for our model. Domains are color coded. N terminal domain (red), 
Stalk domain (orange), 1 B (yellow), Rec 1 (green), Rec 2 (light blue), Connector (dark 
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blue). The region where our compounds are expected to bind is the stalk in the stalk 
domain. The location of one of the resistance residues, Y102, is indicated with the side 
chain. The ADP binding pocket is also marked.  
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Our work characterizing the benzamidine compounds also has the potential to lead to 
further understanding of the divergence between the New- and Old-World alphaviruses. 
The Old-World alphaviruses (e.g., CHIKV) do not show susceptibility to this scaffold as it 
relates to RNA synthesis inhibition. The nsP2102 residue is occupied with a tyrosine in 
New-World alphaviruses (i.e., EEEV, VEEV, and WEEV); while a lysine residue occurs 
at this position in the Old-World alphaviruses. This information provides insight into novel 
ways in which the N-terminal regions of nsP2 and nsP4 may affect the divergent 
phenotypes of the New- and Old-World viruses. Lastly, further research to understand 
the mechanism of ML336 may assist in the design of new compounds that inhibit 
replication of the Old-World alphaviruses.  
In conclusion, we demonstrated that ML336 is a selective and potent inhibitor of 
VEEV viral RNA synthesis and that the inhibition of viral RNA synthesis might be the 
primary antiviral mechanism of this class of compounds. Our results strongly support 
that this class of compounds has a high potential for effective antivirals for New World 
alphaviruses. 
Conclusions 
The previously discovered antiviral compound ML336 was found to inhibit the 
replication of viral RNA by VEEV. This activity appears to be mediated through domains 
of currently unknown function in the N terminal regions of viral nonstructural proteins 2 
and 4. Further characterization of this proposed interaction will be helpful in determining 
the function(s) of this domain which is currently proposed as an accessory domain to the 
helicase. We hypothesize that it will be involved in protein/protein interactions due to its 
location external to the helicase active site, as well as it showing no evidence of RNA 
binding activities.  
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CHAPTER 3 




As outlined in the previous chapter, ML336 and related compounds mediate their 
anti-VEEV activity by inhibiting viral RNA synthesis. Due to the specificity of this activity, 
as well as the fact that viral isolates that resist compound treatment have mutations in 
the N terminal regions of nsP2 and nsP4127, we hypothesize that ML336 and related 
compounds interact with VEEV nsP2 and nsP4. To detect and characterize the 
hypothetical interaction(s) between the amidine compound family and Venezuelan 
equine encephalitis virus (VEEV) it is desirable to determine the location and dynamics 
of this interaction. However, working with VEEV proteins in biochemical assays is 
difficult due to difficulty expressing them recombinantly. This chapter outlines various 
methods that were tested in an attempt to characterize this interaction, as well as the 
development of a system for the ectopic expression of VEEV nsP2.  
Introduction 
While the mechanism of action of our amidine family anti-VEEV compounds has 
been thoroughly examined, the interaction(s) between these drugs and their targets has 
yet to be fully characterized.  Characterizing these interactions will provide more detail 
about the mechanism of action, as well as assist in the further development of this 
compound scaffold. It was hypothesized that ML336 and related compounds interact 
with the nsPs of VEEV. This is due to several observations. First, when viral isolates 
occur that resist treatment with this compound family, the mutations that occur in these 
viruses are primarily focused in nsP2 and nsP4127. This indicates that these regions and 
proteins are important in mediating compound activity. Second, ML336 acts to inhibit 
viral replication and CPE by interfering with viral RNA synthesis. This activity is known to 
be carried out by the viral nsPs. Lastly, ML336 remains activity in a cell-free RNA 
synthesis assay. While this assay does not eliminate all cellular proteins, it does 
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eliminate all living cells. This indicates that the antiviral activity of this compounds is 
unlikely to be dependent on cellular signaling processes.  
 However, the detection of these hypothetical interactions between ML36 and the 
viral nsPs is difficult, as most methods of interaction detection require both large 
amounts of starting material, in this case of viral protein, as well as highly pure sample. 
There are often challenges in expressing eukaryotic, or in this case viral, proteins such 
as insolubility, disulfide bond formation, and post-translational modification174,175176,177, 
and the VEEV nsPs have been historically difficult to generate in this manner, as can be 
seen in only partial expression of nsP2 that has been achieved98,102.  
To date, there has been relatively little success in solving the structures of the 
VEEV nsPs, which makes the prediction of binding sites and interaction using in silico 
methods challenging. While the macrodomain of nsP3, and the protease of nsP2 have 
solved structures102,108,178, the remaining proteins and domains have proven difficult to 
work with and only recently has there been published work examining parts of their 
structure. The N terminal region of nsP2 has recently been crystalized from CHIKV, and 
this allowed for the development of homology models of this protein in VEEV98. A cryo-
em derived structure of nsP1 was also recently published in its membrane bound form92. 
The crystal structure of nsP2 has paired knowledge of protein structure with previous 
research that this protein contains several biologically active domains, in particular the 
C-terminus contains a cysteine like protease domains, while the N terminus has helicase 
and RNA binding activity88,96,162. The C-terminal region of nsP2 also contains a methyl 
transferase like domain, however this domain has not been confirmed to be functional85, 
however it appears to involved in innate immune signaling105. Mutations in this region 
also interfere with the localization of nsP2 to nucleus179 
The determination of protein function and the production of proteins for various 
biochemical assays is greatly aided by the use of vector systems for the expression of 
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proteins. The most common vector system is the use of specially designed strains of E. 
coli that are optimized for this purpose. These systems typically utilize inducible 
expression systems that can be controlled by media supplementation174. There are also 
many strains available that have been optimized for the expression of difficult eukaryotic 
proteins174.  
 With the goal of examining the hypothetical interactions between ML336 and the 
VEEV nsPs, several methods of protein isolation and labeling were attempted. The 
methods that were utilized were fractioning of cells and ultracentrifugation, the labeling 
of proteins and tracking of interactions using Click-iT chemistry, and recombinant 
expression of VEEV nsP2. 
 It was first attempted to purify the nonstructural proteins from infected cells. 
Previous work has established that these proteins could be detected in highly purified 
spherules from infected cells 74. So, we sought to enrich for this fraction from infected 
cells and then determine if we could use this fraction for biochemical binding assays. 
After finding little success with this approach, a recently developed chemical labeling 
system referred to as Click-iT chemistry180 was utilized.  
This chemistry utilizes functional groups that are essentially absent in biological 
systems, azides and alkynes, to perform highly specific interactions which form covalent 
linkages between these groups. These interactions can be used to label molecules for 
imaging, for isolation of molecules form complex mixtures, and many other downstream 
applications. Multiple types of reactions have been optimized both with and without 
copper catalysis. In this instance proteins are metabolically labeled with a methionine 
analogue that can be then be appended using a marker than can then be purified or 
tracked with imaging techniques181182183. This system is advantageous as it can be 
performed during infection easily, and depending on the method used requires minimal 
protein for detection. Working with our medicinal chemist collaborator, we also obtained 
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two compounds, one with efficient antiviral activity and one without, that were modified to 
contain click labile functional groups. This allows for these compounds to be directly 
labeled in the Click reaction and detected in a variety of ways. 
While this system showed promise, being able to detect both metabolically 
labeled proteins as well as specifically appended click labile antiviral compounds, these 
methods were not specific enough for our needs. We detected primarily cellular proteins 
after metabolic labeling, and the click labile compounds were too dispersed throughout 
the cells to make colocalization with viral replication centers or proteins possible. 
Lastly, an expression system was developed for nsP2 and nsP4. The work of 
expressing and purifying this protein was performed iteratively, starting from attempting 
to express fusion peptides of nsP2 and nsP4 in multiple orientations. It was 
hypothesized that these proteins interact in the replicase complex due to resistance 
mutations occurring in both of these proteins in response to treatment with the small 
molecule antiviral compounds.  This initial strategy eventually led to the successful 
expression of the N terminal region of nsP2 using a large solubility increasing tag in a 
highly specialized strain of E. coli termed Rosetta, that has been altered for the 
expression of both proteins with a large number of disulfide bonds as well as for codons 
that are rare in E. coli174.  
Materials and Methods 
Cell culture and viral strains 
Baby hamster kidney (BHK) clone 21 cells (ATCC CCL-10) and Vero 76 (African 
Green monkey kidney fibroblasts) (ATCC® CRL-1587™) were maintained in Modified 
Eagle’s Medium with Earle’s Balanced Salt Solution and L-glutamine (MEM-E, Corning 
10-010-CV) supplemented with 10% fetal bovine serum (FBS) (Corning 35-011-CV). 
Cells were maintained at 37 C in humidified incubators with 5% CO2. VEEV strain TC-83 
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(gift of Dr. Connie Schmaljohn, USAMRIID) was used for this study. The strain V3526 
was generated from a plasmid as described previously (Chung et al., 2014). Infections 
were carried out using a virus infection medium (Modified Eagle’s Medium with Earle’s 
Balanced Salt Solution with L-glutamine (Corning 10-010-CV), 25 mM HEPES, 10% 
FBS) 
Solubilization of the P15 fraction 
Cells were infected with VEEV TC-83 at 10 MOI and incubated for 6 hours. Then, 
cells were washed with ice-cold, sterile PBS (Caisson Labs PBL01) and the cells were 
incubated in hypotonic RS buffer (10 mM NaCl, 10 mM Tris-HCl, pH7.8) supplemented 
with Protease inhibitor cocktail III (Research Products International P50700-1) on ice for 
15 minutes. Cells were scraped into buffer and thoroughly homogenized using a Dounce 
homogenizer. Nuclei were removed by centrifugation at 900 x g for 10 minutes at 4 °C. 
Supernatant containing the cytoplasmic fraction was transferred to microcentrifuge tubes 
and centrifuged at 15,000 x g for 20 minutes at 4 °C. The supernatant (S15 fraction) was 
removed and pellets (P15 fraction) were used for further analysis. 
To solubilize the membranes and release the viral proteins the P15 fraction was 
treated with either Triton X-100 (Sigma Aldrich T-9284) (2% v/v) or sodium deoxycholate 
(Sigma Aldrich 30970) (DOC) (0.5% w/v) with or without 1M NaCl at 4°C for ten minutes 
with mixing at 750 RPM. The insoluble material was then removed by centrifugation at 
15k x G for 20 minutes at 4C. The supernatants were then used in a cell free RNA. 
Method adapted from Pietla et al74 
Isolation of viral proteins via glycerol and sucrose gradients 
Supernatants from DOC solubilized P15 fractions were used as the input material 
for ultracentrifugation over a glycerol gradient. A discontinuous gradient was made using 
three steps 15%, 23%, and 30% glycerol with 1 mM EDTA (Promega V4231) , 50 mM 
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Tris-HCl pH=7.8, 0.5% DOC (w/v) and 150 mM NaCl. Samples were centrifuged at 
100,000 RPM for 1 hour in a Beckmann TLA 110 rotor at 4°C. Ten fractions of 500 µL 
were collected by bottom puncture and those with the highest activity as measured by 
RNA synthesis assay were further separated via a sucrose gradient.  
A three step discontinuous sucrose gradient was used to further separate the 
fractions that were found to have RNA synthesis activity after the initial separation on the 
glycerol gradient. The steps were 15%, 30%, and 60% sucrose (w/v). The samples were 
centrifuged at 100,000 RPM for 6.5 hours in a TLA 110 rotor at 4°C. Ten fractions of 500 
µL were collected by bottom puncture. Fractions were assayed for activity in the RNA 
synthesis assay.  
Isolation of viral proteins using cesium chloride 
Cesium chloride is used to create continuous gradients during centrifugation, and 
separates cellular components based on density rather than migration speed as 
opposed to glycerol and sucrose gradients. An aqueous solution of 1.37 g/mL CsCl was 
made and loaded into centrifuge tubes. The P15 from infected cells was isolated and 
solubilized as described above. The samples were loaded on top of the gradient and 
centrifuged at 100,000 x G for eight hours at 4°C in a Beckmann TLA 110 rotor. Ten 
fractions of 500 µL each were collected by bottom puncture. Floating material that did 
not enter the gradient was also collected.  
Immunoblotting 
The collected fractions after glycerol centrifugation were combined with Laemmli 
buffer (4% SDS w/v, 20% glycerol w/v, 120 mM Tris-HCl pH=6.8, bromophenol blue) 2:1 
and boiled to denature proteins. The prepared samples were loaded into gradient gels 
for SDS-PAGE (GenScript M00656) and run at 150V until the dye front reached the 
bottom of the gel. Protein was transferred to a PVDF membrane (BioRad 1620177) 
using methanol Tris-glycine buffer (200 mM glycine, 25 mM Tris, 10% methanol v/v) for 
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two hours at 20 V. Membranes were washed once with 1X TBS and blocked with 5% dry 
milk in TBS at room temperature for one hour. The membrane was washed five times in 
TBS-0.01% tween 20, and then stained with primary antibody overnight at 4° C. The 
nsP2 monoclonal antibody was used at a final concentration of 0.4 µg/mL diluted in TBS-
T. The membrane was then washed five times with TBS-T and stained with secondary 
antibody diluted in TBS-T. Anti-mouse HRP stained the nsP2 antibody and is used at a 
final concentration of 1:10,000. The secondary antibody staining was performed for one 
hour at room temperature. The membranes are washed six times in TBS-T and 
developed in ECL reagent for five minutes at room temperature. The images were 
collected using an Azure Biosystems c300 imaging system for detection of 
chemiluminescence.  
Cell-free RNA synthesis assays 
VEEV viral RNA synthesis assay was adapted from Barton et al166. Ten 
microliters of P15 fraction enriched for VEEV viral replicase complexes, which is 
equivalent of approximately 1.25 x 106 infected cells, was combined with a same volume 
of a RNA synthesis mix (100 mM Tris-HCl pH 7.8, 100 mM KCl, 20 µg/mL act D, 20 mM 
DTT, 10 mM creatine phosphate (Sigma Aldrich 10621714001) , 50 µg/reaction creatine 
phosphokinase (Sigma Aldrich C3755-3.5KU), 4 mM of ATP, GTP, and UTP, 20 µM 
CTP (NEB N0450s), 12 mM MgCl2) on ice and 1 µL of SUPERaseIn RNase inhibitor 
(Ambion AM2694 ), 5 µg of yeast tRNA (Ambion 15401011), and 5 µCi of [α-33P]-CTP 
(Perkin-Elmer NEG608H) were added per reaction. After an incubation at 37 °C for 90 
minutes, RNA was isolated from each reaction using RNAzol RT and RNA mini prep kit 
columns (Zymo Research R2052) according to manufacturer’s instructions, with an 
additional wash step before elution. For compound addition, ML336 was added to 
reaction mixtures before incubation at 37 °C at the indicated concentrations. The final 
DMSO (Sigma Aldrich D8418) concentration was 0.25%. 
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Silver stain of total protein 
The fractions collected after CsCl centrifugation were mixed 2:1 with Laemmli 
buffer (4% SDS (RPI L22010) w/v, 20% glycerol w/v, 120 mM Tris-HCl pH=6.8, 
bromophenol blue) and boiled to denature the proteins. The prepared samples were 
analyzed by SDS-PAGE in a gradient gel, run at 150 V until the dye front reached the 
bottom of the gel. Gel was stained using the Pierce Silver Stain Kit (Thermo Fisher 
24612) according to manufacturer’s directions. Gel was digitally scanned.  
L-AHA labeling of proteins 
Cells were infected with VEEV TC-83 at an MOI of ten and held on ice for one 
hour. The cells were washed once with PBS and released into warm infection media. 
Infection proceeded for 8 hours. The infected cells were then starved of methionine 30 
minutes before labeling was begun by incubation in DMEM hi-glucose without 
methionine, cysteine, or sodium pyruvate (ThermoFisher 21013024). Cells were then 
treated for one hour with azidohomoalanine (Anaspec AS-63669) (L-AHA) a methionine 
analog which contains an azide, at a concentration of 25 µM. 
DIBO labeling of L-AHA treated cells 
Dibenzocyclooctyne (DIBO) is the catalyst for copper free click chemistry. This 
version of click chemistry is useful because it avoids the off target effects of copper in 
cells184. For labeling of live cells, the cells are washed twice with PBS then DIBO-
Alexafluor 647 (ThermoFisher C20022) in PBS was added to the wells to a final
concentration of 5 µM. The cells were rocked in the dark at room temperature for one 
hour. The cells were washed twice with PBS then lysed with lysis buffer (1%SDS (w/v), 
50 mM Tris-HCl pH = 8). Cells were held in lysis buffer for fifteen minutes on ice, 
suspended and moved to Eppendorf tubes, then sonicated for five minutes in a water 
bath sonicator. The lysate was centrifuged for five minutes at max speed at 4C to 
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remove any debris. For DIBO labeling of cell lysate, DIBO-Alexafluor 647 was added to 
a final concentration of 5 µM to the cell lysate. Lysate was incubated in the dark for one 
hour at room temperature.  
Copper containing Click-iT reaction 
Cells were infected at an MOI of 10 with VEEV TC-83. Cells were held on ice for 
one hour. Cells were washed once with PBS and then released into warm infection 
media. Infection proceeded for 3.5 hours and the cells were methionine starved as 
before. The cells were treated with L-AHA at 25 µM for four hours. The cells were lysed 
as before, and the proteins were precipitated using methanol:chloroform precipitation. 
The proteins were then labeled using the Thermo Click-iT (C10276) protein reaction 
buffer kit according to manufacturer’s instructions. The labeled proteins were separated 
by SDS-PAGE, 150V until the dye front reached the bottom of the gel, and images 
collected using a BioRad Pharos imaging system.  
Treatment of infected cells for fluorescent microscopy 
BHK-21 cells grown on glass coverslips were infected at an MOI of 0.25 and held 
on ice for 1 hour to synchronize infection. Cells were washed with PBS and warm 
infection media was added to initiate infection. Infection proceeded for 5.5 hours at 37C 
and 5% CO2. The media was aspirated, and the cells were pulsed with media containing 
either of the two compounds at 10 µM or 0.25% DMSO vehicle control. Compounds 
3260 and 3261 are derived from the amidine scaffold backbone, they differ in that they 
each contain both an azide and alkyne functional group. The azide is photolabile and 
used to UV fix the compounds to whatever they are bound to in the cell. The alkyne is 
then used from Click chemistry. Cells were incubated for 30 minutes at 37°C 5% CO2. 
The cells were washed for ten minutes in HBSS (Lonza 04-315Q). The cells were short 
wavelength UV fixed for ten minutes to immobilize the compounds. The cells were fixed 
in a one-to-one mix of acetone and methanol at -20°C for 20 minutes in preparation for 
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an immunofluorescence assay (IFA) and to permeabilize the cells. The click reaction 
was then carried out on the monolayer: 1mM CuSO4, 100 mM L-ascorbic acid sodium 
salt, 20 mM Tris-HCl pH=8.5, 20 µM A647 alkyne. 300 µL of the solution was added per 
well, and the plates were incubated in the dark at room temperature for 30 minutes. 
Cells were washed four times with PBS and then used for antibody staining. 
Staining of cells for microscopy 
After the click reaction to directly detect the click labile antiviral compounds, the 
cells were stained to detect VEEV nsP2 and double stranded RNA. The antibodies were 
diluted into PBS with 0.1% saponin (Sigma Aldrich 47036) with 1% normal horse serum. 
Anti-VEEV E protein (BEI) was used at a concentration 1:10,000, and JS1 anti-dsRNA 
antibody (obtained from the lab of Dr. Nobuyuki Matoba as a human FC switched 
antibody) at a concentration of 1:1000. Primary antibody staining was carried out 
overnight at 4°C. The cells were washed three times with PBS-saponin and then stained 
with secondary antibody in the same buffer as before. Anti-goat 555 (gift from the Abu-
Kwaik lab) was used at a concentration of 1:1,000 to stain for E protein while anti human 
488 (JIR 709-545-149) was used to stain for dsRNA at a concentration of 1:1,000. 
Secondary staining was carried out at room temperature for one hour. The cells were 
washed four times with PBS saponin. The cells were incubated with Hoechst stain 
diluted 1:10,000 in PBS for ten minutes at room temperature. Slips were removed from 
the plate and mounted on glass slides using Prolong Gold Antifade mounting medium 
with DAPI (Invitrogen P36931). 
Design of protein expression plasmids 
Initially we deigned pET19.b plasmids that expressed fusions of the N terminal 
domains of nsP2 and nsP4 in two orientations, nsP2-nsP4 and nsP4-nsP2 with a flexible 
linker between the two regions, a map of one such insertion is shown in Figure 17 
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(custom expression plasmids from GenScript). These constructs were insoluble. We 
next attempted to express the N terminal domain of nsP2 as carried out by the Luo lab98. 
Expression of the N terminal domain of nsP2 was performed using the same Pet19.b 
plasmid backbone. The protein construct encoded a his tagged SUMO solubility tag, 
immediately followed by the first 465 amino acids of VEEV nsP2. This construct and 
plasmid backbone is found in Figure 16 (custom expression plasmids from GenScript).  
Strains of bacteria used for expression 
All protein expression experiments were carried out using E. coli. All 
strains are based on the BL21 (DE3) strain of E. coli which contains the genes 
necessary for inducible expression of protein using isopropyl-B-d1-
thiogalactopyranoside (IPTG). Strain BL21 (DE3) was used for expression of the 
expression of the nsP2-4 fusion peptides. E. coli Rosetta (Novagen 70594, gift 
from the lab of Dr. Donghan Lee) was used for expression of the N-terminal 
region of nsP2. 
Expression of the N terminal domain of VEEV nsP2 
The expression vector was transformed into E. coli Rosetta, and then 
used for protein expression. Cultures were grown at 37°C in LB broth to an 
OD600 of 0.4 and induced with the addition of 1 mM IPTG. The cultures were 
shifted to 18°C and then grown overnight. 
Isolation of bacterially expressed proteins 
The bacterial cultures were centrifuged to pellet. Three mL of cell lysis 
buffer was added per gram of E. coli cell pellet (50 mM Tris-HCl pH=8, 1mM 
EDTA (Promgea V4231) pH=8, 500 mM NaCl, 1 mM DTT (Enzo ALX-280-001-
G025))) and the bacteria were resuspended. Four microliters of 100 mM 
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phenylmethylsulphonyl fluoride (PMSF), and 80 µL of ten mg/ml lysozyme were 
added per gram of E. coli. This mixture was agitated for 20 minutes at 4°C. Four 
milligrams of sodium deoxycholate were added per gram of E. coli and this 
mixture sonicated on ice to ensure complete lysis. The lysate was centrifuged at 
5000 RPM for 1 hour at 4°C in a Beckman JS-5.3 rotor. The supernatant is the 
soluble fraction. 
Recovery of protein from inclusion bodies to determine localization during 
expression 
To recover protein from the inclusion bodies, the pellet was resuspended 
in 30 mL of cell lysis buffer 2 (50 mM Tris-HCl pH=8, 10 mM EDTA pH=8, 500 
mM NaCl, 0.5% v/v Triton X-100), and incubated for five minutes at room 
temperature in a water bath. The solution was centrifuged at 5000 RPM for 
twenty minutes at 4°C and the supernatant discarded. This was repeated twice, 
for a total of three washes. The pellet was then washed with 30 mL of water and 
centrifuged as before. 
The supernatant was discarded, and the pellet was suspended in an equal 
volume of inclusion body solubilization buffer (50 mM Tris-HCl pH=8, 1mM EDTA 
pH=8, 500 mM NaCl, 8 M urea, 0.1 mM PMSF freshly added) as the volume of 
the soluble fraction collected. This mixture was stirred at room temperature for 
one hour. Any remaining insoluble material was removed by centrifugation at 
5000 RPM for twenty minutes at 4°C. This is the purified inclusion body fraction. 
Purification of recombinantly expressed protein 
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The expressed proteins contained histidine tags. To purify the desired 
protein nickel column chromatography was used (HisPure Ni-NTA resin Thermo 
Fisher, 88222). Resin was packed into a gravity column and washed and 
prepared according to manufacturer’s instructions. Protein samples were 
equilibrated in PBS with 10 mM imidazole. Increasing amounts of imidazole in 
PBS were used to elute the protein as indicated, ranging from 30 to 310 mM. 
Each elution was three resin bed volumes (3 mL of imidazole solution for 1 mL of 
packed resin). All purification steps were performed at 4°C 
SDS-PAGE analysis of expressed protein 
Protein load was controlled based on OD600 of the bacterial sample. Sample 
was suspended in 100 µL buffer per OD unit. 20 µL of sample was combined with 
Laemmli buffer and separated in gradient gels. Gels were run at 150V until the dye front 
reached the bottom of the gel. Gels were stained with colloidal Coomassie (BioRad 
1610803) 
Results 
Use of purified spherules for detecting the interaction between ML336 and related 
compounds with the VEEV nonstructural proteins 
It has been previously shown that purified spherules from alphavirus infected 
cells contain RNA synthesis activity and contain nsPs74. It was determined that the 
protein contents of these spherules could be purified by centrifugation, and their protein 
contents could be utilized in assays to determine the interaction of the amidine scaffold 
compounds and the nsPs.  
89 
The spherules can be isolated from infected cells by ultracentrifugation. Several 
gradient materials can be used for this purpose. In the case of these experiments, 
glycerol, sucrose, and cesium chloride were used. The proteins that were isolated were 
assayed for activity in the cell free RNA synthesis assay to confirm that their structure 
remained intact. While there was some activity maintained by the isolated protein after 
the initial glycerol separation, this activity was very weak compared to the starting 
material and was completely lost upon further isolation using a sucrose gradient. This 
indicates that structure of the protein complex was disrupted, and they were not suitable 
for further use, Figure 14 A and B. This is likely due to disruption of the proteins during 
the centrifugation process. In previously published work the spherules were kept intact 
during centrifugation74. The disruption of these lipid layers is likely to leave the proteins 
more exposed to damage during the isolation process. Additionally a different media was 
used to form the gradient, a specialized sugar called iodixanol74. This specialized media 
has been used previously for the isolation of live cells185, and its particular properties 
probably assisted to keep the proteins protected.   
There were also issues with the ultracentrifugation being able to isolate the nsPs 
to a single fraction, as shown in Figure 14 C, where nsP2 was detected in multiple 
fractions after ultracentrifugation, indicating that separation across the gradient was 
poor. This poor separation led to our hypothesis that separation by velocity, as in 
glycerol or sucrose gradients, may not be able to separate the cell components 
sufficiently in this case. These results led to our use of a CsCl gradient. This method 
creates a homogenous solution that then creates a density gradient during the 
centrifugation process which separates components based on their densities.  
After centrifugation with CsCl most protein in the cellular extract remained 
floating on top of the solution and did not enter the column, Figure 14 D.  This indicates 
that the proteins were contained in structures that greatly reduced their density. This 
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most likely indicates that despite the initial solubilization to disrupt the lipids contained in 
the extract, enough of them remained intact to interfere with the separation of the 
proteins. After this was unsuccessful, other methods were examined that would allow for 
marking the proteins of interest in the infected cell instead of needing to extract them. 
This led to the use of click chemistry. 
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Figure 14. Isolation of the nsPs from infected cells using ultracentrifugation. A) P15 from 
infected cells was solubilized and separated over a stepwise glycerol gradient. After 
fraction collection the RNA synthesis activity, as measured by CPM using 33P 
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incorporation, was isolated in fractions four and six. B) The active fractions were then 
further separated over a three-step sucrose gradient. After this further separation the 
RNA synthetic activity of these fractions was lost, image from one representative 
fraction. Graphs are from one representative experiment of three C) The nsPs did not 
cleanly separate across a glycerol gradient. After separation across a three step glycerol 
gradient, an immunoblot was performed to detect nsP2. NsP2 was detected in several 
fractions, and in a pellet, P, that occur at the bottom of the centrifuge tube. Ten fractions 
were collected, increasing glycerol concentration from fraction 1 to 10. Image is one 
representative experiment of 2. D) A continuous density gradient made using CsCl was 
also unable to separate the proteins. A solution of CsCl was generated and the 
solubilized P15 fraction loaded on top. After centrifugation ten fractions were collected, 
increasing density from fraction 1 to 10. Fractions collected by bottom puncture. There 
was also a large amount of floating material F, that this did not enter the gradient and 
held a large majority of the proteins. The proteins were also present in a third of fractions 
at roughly equal level, indicating that separation was poor. Total protein was detected by 
silver staining. Isolation with CsCl was only attempted once. 
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The use of click chemistry to label proteins. 
Initially, the labeled proteins were extracted using methanol precipitation and 
then appended with fluorophore using the click reaction. Cells were infected at an MOI of 
ten with VEEV TC-83 for 3.5 hours. The cells were methionine starved for 30 minutes 
and then labeled with L-AHA for 4 hours. Cells were lysed and the proteins isolated 
using methanol precipitation. These proteins were then analyzed by gel electrophoresis, 
Figure 15 A. However, there was poor detection of viral proteins generally, and the nsPs 
could not be resolved, indicating that this method was not sensitive enough to detect the 
proteins of interest specifically compared to the cellular proteins. It is important to point 
out that the specificity of this assay was based on the result of VEEV infection inhibiting 
the synthesis of cellular proteins. However, as can be seen, there was still extensive 
labeling of cellular proteins at the time point examined. Future experiments would need 
to either utilize later time points in infection, or use pharmacological inhibitors of cellular 
protein synthesis. 
As metabolic labeling and in vitro tagging of the viral proteins was poorly 
sensitive and significantly labeled cellular proteins in addition to viral proteins, it was 
determined that altered antiviral compounds that already incorporated one of the 
functional groups would instead be used. Compound 3260 is an effective antiviral 
compound with an EC50 of 1 µM in the CPE prevention assay, compound 3261 is an 
ineffective compound with and EC50 of greater than 50 µM. These compounds are 
derived from the same amidine backbone as ML336. Each contains both an azide and 
an alkyne moiety. The azide is photolabile and allows for the use of UV to fix the 
compounds in place in the cell. This degrades the azide, and then the alkyne is usable 
for click it chemistry. The advantage of this method is that these compounds are not 
subject to the changing efficiencies of metabolic labeling, and the potential association of 
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the compounds and the viral proteins can be observed by co-staining with antibodies 
that detect the viral proteins. Two compounds were used, 3260, which is an effective 
antiviral and was hypothesized to associate with the viral proteins, and 3261 which is not 
an effective antiviral and was predicted to not associate with the viral proteins. 
Cells were infected with VEEV, and then treated with the compounds for 30 
minutes. The cells were then fixed and permeabilized, and the click reaction was 
performed directly on the cell monolayers. The cells were then stained with antibodies 
against E protein and dsRNA to determine the localization of replication and infection 
compared to the antiviral compounds. 
As can be seen in Figure 15 B, there was no significant association between 
either of the compounds tested and dsRNA staining the pink staining, indicating the 
labeled compounds, is distributed throughout all of the cells equally, regardless of 
infections indicated by the yellow E protein or green dsRNA. The pink staining does not 
associated with either of those strains significantly within infected cells. While the active 
antiviral compound is expected to reduce dsRNA detection, due to the short treatment 
time (30 minutes) we had hoped that the compounds would not have taken full effect 
and that some viral replication would have remained active. Ultimately the only 
difference between the treatments was that the effective anti-VEEV compound, 
CB10003260, was able to enter cells at much higher levels compared to the ineffective 
anti-VEEV compound, CB10003261, used as a negative control. Importantly, this assay 
confirmed the antiviral effect of compound 3260, as the cells treated with this compound 
had very little dsRNA staining, indicating an inhibition of viral RNA synthesis. And 




Figure 15. Use of click-iT to identify viral protein/compound interactions. A) Uninfected 
and TC-83 infected cells were metabolically labeled with L-AHA to mark all newly 
synthesized proteins for click it detection. Cells were infected at an MOI of ten for 3.5 
hours and treated with L-AHA for 4 hours before lysis. The click it reaction was 
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performed with DIBO A647 either in the live cells or on cell lysate. Cells were lysed and 
proteins precipitated. Proteins were run in a gel and then imaged with a BioRad pharos 
imager. Only the lysate showed significant click labeling. There was minimal detection of 
viral proteins compared to cellular proteins. One representative image of two 
experiments. B) Representative images of infected cells treated with click moiety 
compounds. Cells were infected at an MOI of 0.25 for 5.5 hours and treated with the 
indicated compounds for 30 minutes at 10 μM. Compound 3260 is active against VEEV 
and enters cells. Compounds 3261 is inactive and does not. There was no significant 
association between the compounds and either viral E protein or dsRNA. Representative 
images of one of two experiments.  
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Expression of recombinant protein for biochemical analysis 
The data from the click chemistry experiments was unable to confirm the 
hypothesis that the amidine antiviral compounds are associating with the nsPs of VEEV 
to mediate their activity. Having gone through several methods attempting to use 
proteins produced during infection, it was determined that we would attempt to 
recombinantly express and purify the proteins of interest. As mentioned above, E. coli 
was selected due to its ease of use and readily available reagents and genetic systems. 
While it was known that expressing nsP2 in particular was likely to be difficult we 
started from an atypical approach of expressing the N terminal regions of nsP2 and 
nsP4 in fusion with one another. This fusion peptide was designed working under the 
hypothesis that these two domains interact closely in the mature replicase complex. This 
was hypothesized because of the high occurrence of compound resistant mutations in 
these two regions. Assuming that the antiviral compound binds to a single location in/on 
the replicase complex, for both of these regions to bind these small molecules they 
would need to be in close association with one another. We thus hypothesized that 
these regions are in close association, and that maintain this association in our protein 
constructs would result in enhanced folding and solubility during bacterial expression. 
Two fusions were created, nsP2-4 and nsP4-2. The expression of these proteins 
was tested in E. coli BL21 (DE3). Maps of the protein constructs discussed here and the 
plasmid backbone used are shown in Figure 16. Neither of these two fusion proteins 
were able to be produced in a soluble manner, with both of them localizing to the 
inclusion body fraction of the E. coli after purification. Figure 17 A shows data from the 
nsP2-nsP4 fusion peptide. Various optimizations were carried out, e.g. altering the 
temperature of induction and the amount of inducer added to the media, but these made 
no difference in the solubility. Refolding was attempted but this was also unsuccessful.  
98 
 
 While the next steps were being determined,  Luo group published the 
crystallization of the N terminal domain of nsP2 from CHIKV, outlining the expression of 
the N terminal domain of nsP2 in a soluble manner by using E. coli Rosetta and a 
solubility increasing tag termed SUMO186. With their assistance, a new expression 
construct was designed that incorporated their methods for expression of the N terminal 
domain of VEEV nsP2. E. coli Rosetta was generously shared by the lab of Dr. Donghan 
Lee, as was a plasmid for the expression of the SUMO protease for removal of the tag 
during purification. As can be seen in Figure 17 B, this new construct was indeed soluble 
when expressed in this strain of E. coli. And in Figure 17 C it is shown that it is also 
readily purified using a Ni column for his tag purification.  
 Large amounts of this protein were synthesized, and then submitted to HPLC for 
final purification before use in binding assays. Unfortunately, after the HPLC was 
performed, there were no peaks detected. Indicating that the protein was somehow lost 
during purification. This could be due to any number of factors. The protein may have an 
affinity for the matrix that was used during the separation process. Granule may have 
formed during the isolation process and clogged the matrix of the column. Or the protein 
could have degraded over the long transit time in the column, resulting in decreased 
concentration and lack of detection. 
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Figure 16. Expression constructs used for ectopic synthesis of VEEV nsP2. A) The 
fusion peptide combining N terminal portions of nsP2 and nsP2. B) The SUMO tagged N 
terminal nsP2 construct that produced soluble protein. C) The pET-19b vector backbone 
that was used for expression, map obtained from GenScript, from which these 
expression constructs were purchased.  
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Figure 17. The expression and purification of VEEV nsP2 in bacterial cells. A) VEEV 
nsP2-nsP4 fusion protein was expressed in BL21(DE3) E. coli. The protein was 
insoluble and formed inclusion bodies. MW=molecular weight, NI= non induced, I= 
induced, IS= insoluble fraction, INC= inclusion bodies, S= soluble fraction. One 
representative image from three experiments. B) The N terminal 465 amino acids of 
nsP2 were expressed solubly using a SUMO tag. The protein expression was evenly 
N-nsP2 
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split between the soluble fraction and the inclusion bodies. One representative image 
from 5 expression batches. C) Soluble nsP2-465 could be purified using Ni-NTA 
chromatography. Optimization of imidazole concentration was only performed once.  
102 
Discussion 
The isolation and use of viral proteins in biochemical and binding assays pose 
several challenges. Primarily, these proteins can often be difficult to isolate from infected 
cells as they occur at relatively low numbers, and like many proteins that are produced in 
eukaryotic systems, they are often difficult to produce using vector systems. However, 
based on previous work that had shown spherules could be successfully isolated from 
infected cells; we attempted to isolate the VEEV nsPs from infected cells directly. 
Unfortunately, this was unsuccessful. 
The use of ultracentrifugation initially showed promise, as there was localization 
of activity from the isolated fraction, but this activity was lost after an additional round of 
purification across sucrose. Several methods were tried to improve this activity, such as 
the addition of viral RNA to serve as more template in the RNA synthesis reactions, 
changing the methods of RNA extraction, and altering the conditions of the synthesis 
itself, such as adding different amounts of radiolabel and rNTPs. None of these 
improved the activity of the fractions appreciably. While CsCl also did not result in good 
separation of the protein, there are other more specialized materials that can be used to 
as gradient material. One of these is iodixanol, a specialized sugar molecule that has 
been previously used in the isolation of biomolecules187. Iodixanol is known to be gentle 
and is even used for preparation of live cells185. Thus the use of this material may result 
more preserved RNA synthesis activity and better preserve the structure of the isolated 
proteins. This would likely result in better maintenance of the enzymatic activity of these 
proteins, allowing for easier tracking during isolation. Gentler separation and isolation of 
the target proteins would also increase the concentration of the protein isolated from 
these infected cells.  
As these attempts at isolating spherules proved impractical, the next attempt at 
detecting the interaction between the amidine compounds and the viral nsPs was carried 
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out using click chemistry. The primary advantage of this method is that the viral proteins 
are labeled in the cell during infection, and that the detection of the labeled proteins is 
highly specific due to use of functional groups that do not naturally occur in biological 
systems. It was hoped that this experiment would result in specific labeling of viral 
proteins, and that this method could then be used to directly isolate these proteins whole 
cell lysate. The first attempt at this labeling, using gel electrophoresis and fluorescent 
labeling detection was unsuccessful. This is due to the fact that the viral proteins were 
not labeling efficiently enough to become apparent in the infected samples versus the 
uninfected control cells. One way that this could be improved is to treat cells later in 
infection. As time goes on, the synthesis of proteins in the cells shifts more towards the 
production of viral proteins. So treatment with L-AHA later in infection should more 
preferentially label viral proteins, allowing for more sensitive detection. 
Due to the poor results from L-AHA labeling, alternative uses of click chemistry 
were investigated. It was found that this method has also been used in fluorescent 
microscopy by performing the click reaction directly in the cell monolayer. Working with 
our medicinal chemist collaborator who is responsible for the synthesis and development 
of the amidine scaffold compounds, she was able to manufacture both an active and an 
inactive compound that were appended with the functional groups necessary for the click 
reaction to occur. This allowed for the design of experiments where the click reaction 
could be performed in combination with staining for VEEV E protein and double stranded 
RNA. While it is true that these compounds are able to inhibit the formation of dsRNA 
due to their antiviral activities, if used for a short enough time, in this case only 30 
minutes, we hypothesized that some replicative activity would remain. This experiment 
allows for the direct determination of compound localization in infected cells and can 
determine if they associate closely with the sites of viral replication. We hypothesized 
that the effective antiviral compound, 3260, would colocalize significantly with dsRNA, 
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which is a readout for the localization of viral replication, and that the ineffective 
compound, 3261, would be dispersed throughout the cell. Unfortunately, these 
experiments proved inconclusive, as the primary difference that was seen between the 
two compounds was that the compound that lacked antiviral effects, compound 3261, 
appeared to be unable to enter cells at the same rate as the effective antiviral 
compound, 3260. Also, further experiments should use a different marker for the 
replicase complexes such as nsP2, as even with the short treatment times used there 
was a significant reduction in dsRNA staining.  
While the results from these microscopy experiments were inconclusive, they 
resulted in the development of several new tools for further experiments. First, the click it 
reaction was successfully performed on a cell monolayer, and if the L-AHA or other 
metabolic labeling can be optimized, these can be combined to great effect. Second, 
these experiments led to the optimization of the use of a dsRNA antibody. This antibody 
is highly useful as it only stains those cells that are undergoing active viral replication, 
compared to cells that express viral protein. This antibody can also be used for 
colocalization studies to identify the loci of viral replication within infected cells.  
The inconclusive results of the click experiments led to the work developing an 
expression system of VEEV nsP2 in E. coli. As outlined above, it was determined that 
the N terminal domain of the protein could be expressed in a soluble manner when fused 
to a SUMO tag. However, this took quite a bit of optimization of both the constructs and 
expression system. The first attempt was made using nsP2 and 4 fusion constructs. 
These constructs were readily expressed at high levels but were never able to be 
expressed in a soluble form, and refolding these proteins was also unsuccessful. Even in 
the Origami strain of E. coli which is designed for the expression of proteins that contain 
disulfide bonds and that typically don’t fold correctly in expression vectors, this construct 
remained insoluble and disordered.  
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This resulted an impasse until we incorporated the SUMO tag. This tag proved 
quite helpful in the expression of this protein. The resulting truncated protein constructs 
were produced in the soluble fraction of E. coli Rosetta at high concentrations. However, 
when this tag was used with full length nsP2 protein and not the truncated construct, it 
remained insoluble. If the full length nsP2 is required for future experiments, further 
optimization of this expression will need to be carried out. NsP4 was also expressed in 
this same system with a SUMO tag, and it too remained insoluble. 
Additionally, the SUMO tagged nsP2 truncated construct had some issues with 
its purification. As shown, the complete construct can be readily purified using Ni 
chromatography. However, upon digestion with the SUMO protease, there is significant 
loss of protein sample, indicating that either the digestion, or the purification step 
performed to remove the tag need additional optimization. One way that this may be 
improved could be to incorporate a different protease site, such as an EK site, between 
the tag and nsP2. The use of a different cleavage method may result in a higher fidelity 
reaction. Different proteases also have different reaction conditions which may prove 
more suitable for our protein constructs, and result in less loss due to degradation. Also, 
a portion of the Ni chromatography purified protein was submitted for HPLC purification. 
Interestingly, despite a large protein input there were no peaks indicating proteins 
release from the column, and this was confirmed using the Bradford reaction. If HPLC is 
to be performed again, it is likely that the protein is binding to some part of the column, 
and so a different matrix types should be investigated. This protein construct may also 
have general issues of stability due to its nature as an incomplete truncated peptide. 
This would make slow purification schemes difficult. This should be examined further. 
Lastly, the SUMO containing protein construct can be used as is for many 
different assays, such as surface plasmon resonance, which allow for the measurement 
of binding of the antiviral compounds and the protein construct. Pilot studies were 
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performed using the OpenSPR platform from Nicoya, but unfortunately the sensitivity of 
the assay was poor, leading to inconclusive data. This is most likely due to the size of 
the antiviral molecules, as they are quite small, making the detecting of binding more 
difficult that with larger interactors. If these experiments are to be continued, then further 
work to increase the sensitivity of the assay should be performed. Such as by using 
various treatments to increase the amount of protein construct immobilized on the chip, 
or by immobilizing the small molecules on the chip and associating the protein construct. 
Conclusions 
Though this work attempting to detect and characterize predicted binding 
between the VEEV nsPs and the amidine scaffold was unsuccessful, it did lead to 
several useful experimental developments. First, the use of click chemistry in assays 
using both metabolic labeling of proteins and fluorescent microscopy was developed. 
While this chemistry did not prove useful for the experiments described here, these 
assays have many potential uses both monitoring the synthesis and localization of 
proteins as well as compound localization. There are also potential uses of this 
chemistry for directly purifying labeled proteins and compounds from cells and complex 
mixtures and extracts. Several additional tools were developed in tandem with these 
assays, including the use of a double stranded RNA antibody to track viral replication, 
and the novel amidine compounds that have click moieties that have potential to be used 
in many different experiments for both detection and purification. Second, an expression 
system for the N terminal domain of nsP2 was developed. This protein construct can be 
produced in large amounts as a soluble protein. This expressed protein is then readily 




THE USE OF AMIDINE COMPOUNDS TO CHARACTERIZE A REGION OF 
UNKNOWN FUNCTION IN VEEV NSP2
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Overview 
While antiviral drugs are researched primarily for their potential uses as 
therapeutic compounds, these compounds can also be used in viral research in a variety 
of ways dependent on their mechanisms of action. One way that these molecules can be 
utilized is to probe viruses for novel biological functions that have yet to be described. In 
this chapter, the amidine family of compounds characterized in chapter two has been 
used to probe the biology of VEEV. In this chapter the isolation and sequencing of 
viruses that resist the effects of these compounds will be discussed. Then these isolates 
will be used to characterize the function of an N terminal region of the viral nsP2, which 
previously has not been characterized and lacks designated functions.  
Introduction 
Despite the apparent simplicity of many viruses, the study of their biology can be 
quite complex. This is due to several factors, such as the uniqueness of many viral 
proteins making the use of homology modeling and functional prediction difficult, as well 
as the fact that viruses are dependent on cellular processes for many parts of their life 
cycles, meaning that functional assays of the viral proteins may not reveal all of the 
functions that they perform. Many viruses are also incredibly efficient in the use of their 
genetic material, generating proteins that are multifunctional, with many interacting 
domains. The result of this is that even many well studied viruses have portions of their 
genomes and proteins that have yet to be functionally characterized. This includes 
alphaviruses. These viruses were first isolated in the 1930s26,188–190 and have been 
thoroughly studied since, yet many parts of their proteins remain enigmatic. This 
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difficulty in characterizing these regions necessitates the development of novel ways to 
probe viral biology in addition to traditional biochemical and virological methods. 
One way that viruses are characterized in our lab is by using the antivirals that 
have been developed with our collaborators to perturb the viral life cycle. Due to their 
rapid mutations rates191 RNA viruses will often escape treatment with any antiviral 
compound, leading to generation of resistant populations that contain mutations in their 
genomes192. These mutant viral populations can then be plaque purified, and their 
genomes examined for mutations. In this work the Oxford Nanopore system has been 
utilized for sequencing of resistant viral isolates. This system is advantageous due to the 
small amount of starting material that it requires, as well as the fact that viral RNA can 
be sequenced directly.  
Viruses that were resistant to the amidine family of compounds described in 
chapter 2 were isolated. After sequencing of these mutant populations, it was found that 
these viruses had mutations that were localized in the N terminal region of nonstructural 
proteins (nsP) 2. It was surprising to find mutations in this region because it currently 
lacks any predicted or described function.  
NsP2 has been characterized as both the viral helicase protein as well as a 
cysteine protease88,96,98,162,193. However, a large portion of the N terminal region remains 
undefined. There has been some progress in solving the structure of this protein using 
X-ray crystallography, with the C terminal protease region being solved in Venezuelan 
equine encephalitis virus (VEEV), and recently the N terminal half of the protein was 
crystalized from chikungunya virus (CHIKV)98,193,194. However there has yet to be a 
structure solved for the entire protein. The structure of CHIKV nsP2 indicates that the 
helicase and its accessory domains take up a large portion of the N terminal region. 
From N to C-terminal these domains are: the N-terminal domain, the stalk domain, 1 B, 
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Rec 1, Rec, 2, and the connector domain.  The 1 B, Rec 1 and Rec 2 domains are all 
involved in the RNA binding and helicase activity of the enzyme. However, the 
disordered N-terminal domain and the stalk domain lack known fucntion98. Of the 
mutations that occur in nsP2 that result in resistance to compound treatment, the 
majority are in the N-terminal and stalk domains, such as those at amino acid position 65 
and 102, with some being in the far N terminal portion of the Rec 1A helicase accessory 
domain, amino acid 116, far from the helicase active site, and arrayed primarily on the 
external faces of the protein.  
 For the purpose of this work, three viral isolates with mutations that occurred in 
nsP2 were selected. These mutants were characterized in a variety of classical 
virological methods, investigating their growth, RNA synthesis phenotypes, and protein 
expression. Initially, this characterization was carried out using baby hamster kidney 
cells, a cell line that has long be used in the study of alphaviruses due its high 
susceptibility and permissivity to infection195–197198..  
After this initial characterization was completed the potential attenuation of these 
viruses was also examined in a neuronal cell model, SH-SY5Y cells. Neurons are a 
major cell type targeted by VEEV and are important in its pathology, and the effects of 
mutations in the nsPs may vary in these cells when compared to fibroblasts. SH-SY5Y 
cells are a human neuroblastoma cell line derived from metastatic cancer199. This cell 
model has an active viral response system while still being susceptible and permissive to 
infection with multiple viruses200–20237. These cells also have the advantage of being able 
to be differentiated into mature neurons203201. These differentiated cells are a reasonable 
facsimile of mature neurons in the brain203–205. This phenotype indicates that these cells 
provide a readily available, biologically relevant model of alphavirus infection of neurons.  
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Materials and Methods 
Fibroblast cell culture and viral strains 
 Baby hamster kidney (BHK) clone 21 cells (ATCC CCL-10) and Vero 76 (African 
Green monkey kidney fibroblasts) (ATCC® CRL-1587™) were maintained in Modified 
Eagle’s Medium with Earle’s Balanced Salt Solution and L-glutamine (MEM-E, Corning 
10-010-CV) supplemented with 10% fetal bovine serum (FBS) (Corning 35-011-CV). 
Cells were maintained at 37 C in humidified incubators with 5% CO2. VEEV strain TC-83 
(gift of Dr. Connie Schmaljohn, USAMRIID) was used for this study. Infections were 
carried out using a virus infection medium (Modified Eagle’s Medium with Earle’s 
Balanced Salt Solution with L-glutamine (Corning 10-010-CV), 25 mM HEPES, 10% 
FBS) 
Undifferentiated SH-SY5Y cells 
SH-SY5Y cells are human neuroblastoma cells derived from metastatic cancer 
isolated from the bone marrow of a patient. Cells were grown on cell culture treated 
plates and maintained in at 37°C 5% CO2. Cells were obtained from ATCC (CRL-2266). 
Cells were maintained in EMEM with 15% FBS, 1x penicillin/streptomycin, 2 mM 
glutamine. Cells were infected with the same media.  
Differentiation of SH-SY5Y cells 
Differentiation of SH-SY5Y cells into mature neurons has been well documented 
previously200,203,204,206–208. Cell were plated on untreated cell culture dishes (day 0). The 
following day (day 1) media was changed to differentiation media 1. Media was changed 
on days 3 and 5. On Day 7 cells were split 1:1, all with differentiation media 1. Day 8 
media was changed to differentiation media 2. Day 10 cells were split 1:1 onto dishes 
coated with extracellular matrix with differentiation media 2. Day 11 media was changed 
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to differentiation media 3. Media was changed on days 14 and 17 with differentiation 
media 3. On Day 18 cells are mature and ready to use. Differentiation media 1: EMEM 
with 2.5% FBS, 1x Penicillin/Streptomycin, 2 mM glutamine, 10 µM retinoic acid 
(STEMCELL technologies 72262). Differentiation media 2: EMEM, 1% FBS, 1x 
Penicillin/Streptomycin, 2 mM glutamine, 10 µM retinoic acid. Differentiation media 3: 
Neurobasal media, 1x B-27, 20 mM KCl, 1x Penicillin/Streptomycin, 2 mM GlutaMAX, 50 
ng/mL brain derived neural growth factor (Sigma Aldrich B3795), 2mM dibutyryl cyclic 
AMP (Selleck Chemicals S7858), 10 µM retinoic acid. Cells were infected in 
differentiation media 3.  
Plaque purification of resistant viral isolates 
Vero 76 cells were infected with VEEV TC-83 in the presence of 20 µM 
CB1000905. Supernatant was collected and then used for plaquing with an agarose 
overlay, also with 20 µM CB1000905. Plaques were picked and then placed in virus 
infection media to allow the virus to diffuse out of the agarose. These samples were then 
used to infect monolayers again under compound selection. This process was repeated 
a total of three times.  
Sequencing of whole viral genomes with the MinIon platform 
Vero 76 cells were infected at an MOI of ten with VEEV TC-83 and treated with 
compound CB1000905 at 20 µM. The media was aspirated, and TRI reagent was added 
at 300 µL per well and the cells were homogenized by pipetting. The RNA was then 
isolated using a ZYMO mag bead RNA isolated kit according to manufacturer’s 
instruction (R2101). Ribosomal RNA was depleted from the samples using an NEBNext 
rRNA depletion kit (NEB E6310S) according to manufacturer’s instructions. This RNA 
was used as input for direct RNA sequencing using an Oxford Nanopore direct RNA 
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sequencing kit (SQK-RNA002) according to manufacturer’s instructions. Sequencing 
was performed using the Oxford Nanopore MinION platform. Sequences were analyzed 
using Integrative Genomics Viewer209–211. 
Viral growth kinetics 
BHK-21 cells were seeded into 6 well plates at a density of 400,000 per well. 
Plates were infected at an MOI of 0.05 with the indicated virus and placed on ice for one 
hour to synchronize the infection. Inoculum was 0.5 mL. The cells were washed once 
with PBS and warm media was added to initiate the infection. The infection proceeded at 
37°C 5% CO2. Supernatant was collected at the indicated times and used for titration by 
plaque assay.  
For infections of the SH-SY5Y, virus had to be diluted into media corresponding 
to the needs of either the undifferentiated or differentiated SH-SY5Y cells. Cells were 
grown in 24 well plates and infected at a volume of 300 µL. The virus was diluted into the 
corresponding media, for undifferentiated cells EMEM with 15% FBS, 1x 
penicillin/streptomycin, 2 mM glutamine was used. For differentiated cells differentiation 
media 3 was used. Cells were inoculated at either MOI 5 for single step growth analysis 
or MOI 0.05 for multistep growth analysis. The cells were incubated at 37°C 5% CO2 for 
one hour. The media was aspirated, and the cells washed with the corresponding media 
free of virus. Warm media was added, and this point was considered time zero for the 
infections. Supernatant was collected at the indicated times post infection, and these 
samples were used for plaque assay titration.  
Plaque assay titration 
Plaquing for titration of the viruses was carried out on Vero76 cells in 24 well 
plates. Cells were seeded at a density of 100,000 per well and allowed to grow overnight 
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in complete media. Samples for titration were diluted in VIM (Modified Eagle’s Medium 
with Earle’s Balanced Salt Solution supplemented with 25 mM HEPES and 10% FBS).   
and vortexed. 167 µL of inoculum was used per well in 24 well plates. Media was 
aspirated from the cells and the dilute samples added and then incubated at 37°C, 5% 
CO2 for one hour. Plates were rocked initially and after 30 minutes. After one hour the 
cells were washed with PBS and overlay was added. For titration methyl cellulose 
overlay media was used (EMEM, 10% FBS, 0.7% w/v methyl cellulose, 1x GlutaMAX, 15 
mM HEPES). These plates were then incubated at 37°C 5% CO2 for three days, and 
then stained and fixed with a solution of 2% paraformaldehyde, 0.8% crystal violet in 
ethanol, dissolved in PBS.  
Plaque size analysis 
To measure the relative size of plaques of the viral isolates the protocol above 
was modified. Vero 76 cells were seeded at a density of 400,000 cells per well in six well 
plates. Samples were diluted in VIM and 668 µL of inoculum was added per well. Cells 
were incubated and washed as above. One mL of overlay media was added per well: 1x 
EMEM (Gibco 11430-30), 0.6% agarose (MP Biomedicals 952012), 0.22% sodium 
bicarbonate (Gibco 25080-094), 1x GlutaMAX, 1x nonessential amino acids (Gibco 
11140050), 1x penicillin/streptomycin (Gibco 15140122), 15mM HEPES, 10% FBS. The 
plates were incubated at 37°C 5% CO2 for 2 days and fixed with 4% paraformaldehyde 
at 4°C. The cells were then stained with 2% paraformaldehyde, 0.8% crystal violet in 
ethanol, dissolved in PBS. The plates were scanned, and the images used for plaque 
size analysis and counting using the viral plaque plugin for ImageJ/FIJI212. 
Isolation of viral RNA for qRT-PCR characterization 
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BHK cells were infected at an MOI of ten. The cells were placed on ice for one 
hour to synchronize infection. The cells were washed with PBS and then warm media 
was added to initiate infection. The cells were placed at 37°C 5% CO2 for the indicated 
times. At the indicated times, the media was aspirated, and TRI reagent (ZYMO R2050) 
added at 300 µL per well and the cells were homogenized by pipetting. The RNA was 
then isolated using a ZYMO mag bead RNA isolated kit according to manufacturer’s 
instruction (#R2101).  
cDNA synthesis for qRT-PCR analysis 
RNA samples were isolated as described above. Two master mixes were made as 
follows: 
Master Mix 1: 
Reagent Amount per one reaction (µL) 
10 mM dNTPs (Promega U1515) 1 
Custom primer (10 pmol/µL) or 
random hexamer (40pmol/µL) 
1 
Nuclease free water 4 
Four µL of RNA was added to this master mix and the reaction was heated at 65 C for 5 
minutes. The reaction was then chilled on ice for 5 minutes. 
Master Mix 2: 
Reagent Amount per one reaction (µL) 
5X reverse transcriptase buffer 
(ThermoFisher EP0743) 
4 
SUPERaseIn (Ambion AM2694) 0.5 
Maxima H Minus Reverse 
Transcriptase (ThermoFisher EP0743) 
0.5 
Nuclease free water 5 
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Ten µL of master mix two was added to each reaction after chilling. The reaction as 
gently mixed and then submitted to the following protocol for cDNA generation and 
thermal degradation of RNA: 
1. 25oC for 5 min.  
2. 50oC for 60 min.  
3. 85oC for 5 min.  
4. 4oC hold  
This cDNA was then used for further analysis in qRT-PCR analysis as described below. 
Strand-specific quantitative real-time PCR (qRT-PCR) of VEEV RNA  
Detection of positive and negative sense, genomic viral RNA was carried out 
using a strand-specific qRT-PCR method adapted from Plaskon et al165. Briefly, cDNA 
was generated using tagged primers for detecting positive-sense and negative-sense 
RNA. The generated cDNA was then used in qRT-PCR using TaqMan chemistry with a 
strand-specific primer set.. A fluorescent probe was used for both analyses. PCR 
reaction was performed using Fast Advanced TaqMan master mix (Applied biosystems 
4444557). PCR cycles were performed according to manufacturer’s instructions. The 
primer sequences are given in the following table. Lowercase sequences are additional 
sequence added for primer identification, sequences in italics are specific for viral RNA, 
and sequences in bold were used to identify only those cDNA sequences that were 
produced due to primer binding. All primers and probes were custom ordered from IDT. 
Primer Sequence 










aataaatcataa GGC AGT ATC GTG AAT TCG ATG C 
nsP1 negative 
FWD 
aataaatcataa GGC GAC TCT AAC TCC CTT ATT G 
nsP1 negative 
REV 
aataaatcataa GGC AGT ATC GTG AAT TCG ATG C 
nsP1 probe /56-FAM/TCC GTC AAC /ZEN/CGC GTA TAC ATC CTG /3IABkFQ 
qRT-PCR analysis of subgenomic RNA synthesis 
RNA samples from six hours post infection were used. cDNA was generated 
from RNA isolated from infected cells as described above using random hexamer. This 
cDNA was then used in a multiplex qRT-PCR with the following primers and TaqMan 
probes with TaqMan Fast Advanced master mix. All primers and probes were custom 
ordered from IDT.  
Primer Sequence 
Capsid FWD GGACGACCCATTCTGGATAAC 
Capsid REV CGTTCCACATGACGACTGAA 
Capsid Probe /5SUN/TCCTTCATT/ZEN/CACACCTCCCAGCAC/3IABkFQ/ 
nsP1 FWD CTGACCTGGAAACTGAGACTATG 
nsP1 REV GGCGACTCTAACTCCCTTATTG 
nsP1 Probe /56FAM/TCCGTCAAC/ZEN/CGCGTATACATCCTG/3IABkFQ 
The double delta CT was calculated and used to generate the relative gene expression 
that is shown.  
Immunoblotting 
Whole cell lysate from infected cells was collected by directly lysing cells with 
Laemmli buffer in the plate (2% SDS w/v, 10% glycerol w/v, 120 mM Tris-HCL pH=6.8, 
bromophenol blue)213. The resulting lysate was homogenized by pipetting. Samples were 
loaded into gradient gels for SDS-PAGE (GenScript M00656). Samples were run at 
170V until the dye front was run off of the gel. Protein was transferred to a PVDF (Biorad  
1620177) membrane using methanol Tris-glycine buffer and a semi-dry blotting 
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apparatus, 18V for 35 minutes. Membranes were washed once and blocked with 5% dry 
milk in TBS. The membranes were washed five times in TBS-T and then stained with 
primary antibody overnight at 4 °C. Anti-nsP2 E3 antibody (purified custom polyclonal 
antibody from GenScript) and anti-E protein polyclonal antibody (BEI) were both used at 
a 1:1000 dilution in TBS-T. The membranes were then washed five times with TBS-T 
and stained with secondary antibody diluted in TBS-T. Anti-rabbit HRP (Santa Cruz 
Biotechnology Sc-2054) was used to detect the nsP2 antibody and is used at a final 
concentration of 0.01 mg/mL. Anti-goat HRP (SeraCare) was used to detect the E 
protein and was used at a concentration of 1:10,000. Actin was stained directly using an 
HRP conjugated antibody (CellSignal 8H10D10) final dilution 1:10,000. The secondary 
antibody staining is performed for one hour at room temperature. The membranes are 
washed six times in TBS-T and developed in ECL reagent for five minutes at room 
temperature (ECL reagent A: 2.5 mM luminol, 400 mM P-coumaric acid, 100 mM Tris-
HCL pH=8.5. Reagent B: 0.02% H2O2, 100 mM Tris-HCl pH=8.5. Mix A and B one to 
one for development). The images were collected using an Azure imaging system for 
detection of chemiluminescence. For staining of the E protein, the membranes 
previously stained for actin and nsP2 were stripped in acid stripping buffer (1% w/v SDS, 
25 mM glycine HCL pH=2) for 30 minutes at room temperature with rapid agitation, and 
washed twice with PBS, and once with TBS-T before proceeding with blocking and 
staining.  
Statistics 
Statistics were performed in GraphPad Prism version 9. Unless otherwise 
indicated significance was calculated using ANOVA with Dunnett corrections for multiple 
comparisons. Error is reported as standard deviation. Graphs represent mean values of 
the indicated number of experiments. 
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Results 
Compound resistant viral isolates of VEEV have mutations in nsP2 
 Previous work with the antiviral compounds in our lab has identified the locations 
of mutations that occur in viral isolates that resist compound treatment which were 
isolated via plaque purificaiton148. Three isolates were selected that were known to have 
mutations in nsP2, to focus on characterizing unknown activities of this protein. After the 
initial selection, these viruses were submitted to whole genome sequencing to determine 
if there were any additional mutations in their genomes that had not been previously 
discovered. This process utilizes a direct RNA sequencing method developed by Oxford 
Nanopore for use with their MinION platform.  
It was found that mutations occurred in multiple locations in each of the selected 
viral isolates. Two of the isolates had single mutations in nsP2 at Y102 and D116. Both 
of these isolates also had point mutations in their E proteins. The third selected isolate 
had two mutations in nsP2 at both Y65 and Y102. This isolate also had a single point 
mutation in the subgenomic promoter region. While this is a noncoding region in the viral 
RNA it is highly important due to its regulation of subgenomic RNA synthesis. This led to 
the hypothesis that this mutant isolate is likely to have significant alterations to its 
expression of the structural proteins. The nucleotide sequence of the area of nsP2 that is 
mutated is shown in Figure 18, nucleotide changes are shown in red, and the position of 
the nucleotide is indicated. Maps of the viral genome are shown in Figure 19, with each 
of the mutations indicated. Table 3 lists the selected isolates with their mutations.  
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Figure 18. Single nucleotide polymorphisms of the selected viral isolates in N-nsP2. The 
sequences of VEEV TC-83 as well as the three selected mutant isolates are shown. The 
mutated nucleotides are shown in red and the poisitons boxed in. The nucloetide 
position is below the selected bases. All of the selected amino acid changes are due to 
single nucleptide polymoorphisms. 
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Figure 19. Maps of the full length genomes of the selected mutant viruses. A) Simplified 
map of isolate 82_11_24. Sequencing found a mutation, D116N located in the 1 B 
domain in nsP2, and there was an additional point mutation in E1. B) Simplified map of 
isolate 81_12_24. Sequencing found a mutation, Y102C located in the stalk domain in 
nsP2, and there was an additional point mutation in E2. C) Simplified map of isolate 
6_13_25. Sequencing found two mutations, Y65C in the N-terminal domain and Y102C 
122 
in the stalk domain in nsP2. There was an additional SNP in the region corresponding to 




















TC-83 --- --- --- --- --- --- --- 
82_11_24 --- --- N --- --- S 1124 
81_12_24 --- C --- --- Y --- 1224 
6_13_25 C C --- T --- --- 1325 
Table 3. Selected resistant viral isolates. Mutations are as indicated. 
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Compound resistant mutant viruses displayed delayed growth in a fibroblast cell 
model.  
The three mutant viruses were expanded under compound selection to ensure 
that the mutations were maintained through passaging. BHK cells were then infected at 
an MOI of 0.05 and a growth kinetics assay was performed using plaque assays to 
determine viral titer. It was hypothesized that isolate 6_13_25, with the subgenomic 
promoter mutation, would have a significant reduction in growth due the predicted effect 
this mutation would likely have on structural protein expression. However, the mutant 
isolates did not demonstrate a reduction in maximum titer compared to TC-83, Figure 20 
A. Instead each virus eventually reached and maintained a titer that was similar to the 
parental strain. These mutations did, however, result in delayed growth compared to the 
parental control TC-83. Isolates 82_11_25 and 81_12_24 both had delayed viral 
production, but quickly caught up to TC-83. 6_13_25 was the most significantly delayed 
and took the longest to reach parity with TC-83, Figure 20 A. These results show that the 
mutations found in the resistant viral isolates lead to a growth delay, with slower 
infection, and production of infectious virus, but not a growth defect in this non-selective 
cell line.  
While performing the plaque assays for the growth kinetics analysis, plaque 
morphology changes were noted in isolate 6_13_25. To examine this in greater detail, 
agarose plaque assays in 6 well plates were used, Figure 20 B. This analysis showed 
that 6_13_25 did in fact have smaller plaques than the other isolates or TC-83, Figure 20 
C. This is not surprising, as the structural proteins, and capsid in particular, are very 
important to the biological activities of alphaviruses and are under control of the 
subgenomic promoter7,55. The capsid protein is also very important in inducing cytopathic 
effect, detected phenotype in plaque assays80. These plaques also had a much tighter 
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distribution compared to TC-83 or the two single mutants. This phenotype indicates that 
isolate 6_13_25 is significantly attenuated compared to TC-83 and is less fit for cell to 
cell spread or cytopathic effect, in addition to the growth defect that it shares with the 
isolates that lack the subgenomic promoter mutation. Isolates 81_12_24 and 82_11_24 
have more moderate attenuations. 
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Figure 20. Mutant viral isolates show delayed growth in a fibroblast cell mode, and 
isolate 6_13_25 has decreased plaque size. Three mutant viruses were selected with 
the indicated mutations in nsp2. BHK cells were infected at an MOI of 0.05 A) All of the 
mutant viruses showed a delay in the production of new infectious virus as measured by 
plaque assay. Isolate 6_13_25 showed a larger delay than either of the two single 
mutants. Kinetics data combined from two experiments, three biological replicates per 
time point per experiment. 48 HPI was only collected from one experiment B) 
Representative images of plaque morphology from each of the viruses using an agar 
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overlay and staining the monolayers with crystal violet. Representative of three 
experiments. C) Quantification of the relative size of the plaques from each virus. The 
double mutant shows plaques that are significantly smaller than those of the parental 
TC-83 strain. The single mutants show no change. Graph is from one representative 
experiment of three. Three biological replicates per experiment. P<0.0001 as calculated 
by one way ANOVA. 
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Compound Resistant Viral Isolates Show Alterations in Their RNA synthesis 
profiles 
NsP2 is highly important in the RNA synthesis of alphaviruses, acting as the RNA 
helicase of these viruses and having RNA binding activity (described in detail in chapter 
1). Having noted a delay in growth of these resistant isolates, it was hypothesized that 
this growth delay resulted from a defect in viral RNA synthesis, likely being mediated by 
the mutations that occur in N terminal region of nsP2. 
Alphaviruses produce both positive and negative-sense RNA for replication82. 
These strands are both synthesized by the nonstructural proteins, but this synthesis is 
tightly controlled58,59,61,160,214. Thus, the synthesis of these two strands was examined 
separately, using a modified RT-PCR that is able to discriminate between the two 
different of polarities of RNA.  
It was found that both isolate 81_11_24 and 6_13_25 had delayed production of 
positive-sense RNA, Figure 21. This was similar to growth kinetics phenotypes. With the 
detection of the positive sense RNA being delayed early in infection and catching up to 
the parental virus strain by 8 hours post infection. That both of these isolates show this 
delay indicates a likely involved of the N terminal domain of VEEV nsP2, as isolate 
81_11_24 lacks the significant mutation in its subgenomic promoter. However, only 
isolate 6_13_25 showed a significant delay in the synthesis of negative-sense RNA, 
Figure 22. This indicates a likely involvement of nsP2 Y65C in the synthesis of negative-
sense RNA as only this isolate contains this mutation, and this synthesis should not be 
affected by the subgenomic promoter. 
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The relative expression of the subgenome was also examined, Figure 23. This 
was quantified by comparing the ratio of subgenomes to genomes in each of the viral 
isolates and TC-83. It was hypothesized that isolate 6_13_25 would have significant 
alterations in subgenomic RNA synthesis levels due to the mutation in the subgenomic 
promoter. While the other two isolates have point mutations in their glycoproteins, these 
proteins are not involved in RNA synthesis, so it was unlikely that the synthesis of the 
RNA would be effected. It was found that isolate 6_13_25 had greatly reduced 
subgenomic RNA expression, producing virtually no subgenomes at the time point 
examined, and the two other isolates displayed similar ratios to the parental TC-83 





Figure 21. Mutant viral isolates have a delay in positive-sense RNA synthesis. Strand 
specific qRT-PCR was performed at the indicated times post infection. Isolates 
82_11_24 and 6_13_25 both show reduced levels of positive-sense RNA at two and four 
hours post infection. This difference is lost at eight hours post infection, by which time 
every strain has reached the same level of RNA Data from one representative 
experiment of three. Three biological replicates per experiment. *p<0.05, **p<0.01, 
***p<0.001 as measured by one way ANOVA.  
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Figure 22. Isolate 6_13_25 has a delay in negative-sense RNA synthesis. Strand 
specific qRT-PCR was performed, and the amount of negative sense viral RNA 
quantified. Isolate 6_13_25 was found to have reduced negative sense RNA at two and 
four hours post infection. This difference was no longer present at eight hours post 
infection. Data from one representative experiment of three. Three biological replicates 
per experiment. * p<0.05, **p<0.01 as measured by one way ANOVA.  
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Figure 23. Relative expression of the subgenomic RNA compared to genomic RNA. 
Expression of capsid RNA was quantified relative to the expression of nsP1. This 
relative expression was then compared between the mutant viral isolates and TC-83. 
Only isolate 6_13_25 is significantly different from TC-83 with a ratio of one half that of 
the parental strain, indicating there is little to no subgenomic expression at this time. 




Viral Isolates with mutations in nsP2 have altered protein expression profiles 
 Having investigated both the growth and RNA synthesis profiles of these 
compound resistant viral isolates, the next step was to examine their protein expression. 
The finding that two of these isolates had altered RNA synthesis led to the hypothesis 
that they would have similar delays in the expression of the viral proteins, indicating that 
a delay in replication of the viral RNA was leading to the delay seen in viral growth 
kinetics. In addition, it was expected that there would be marked decrease in the 
structural proteins of isolate 6_13_25 due to large decrease in its transcription of the 
subgenomic RNA. While there was not a statistically significant delay in RNA synthesis 
in isolate 81_12_24, it did have a delay in growth kinetics and displayed a trend of 
reduce positive-sense RNA synthesis at early times points, so it was expected to show a 
delay in protein synthesis as well.  
 To examine viral proteins synthesis, immunoblotting was performed. Nsp2 was 
used as a marker of the expression of the viral nonstructural gene and has been 
previously used by our lab in this manner66. The E protein was used as a maker for the 
expression of the viral structural protein, the antibody used here stains both the E1 and 
E2 proteins. Beta actin was used as a loading control, and its intensity was used to 
quantify the relative expression of the viral proteins across the different samples.  
 Protein expression was examined in BHK cells, which were infected at an MOI of 
ten and then lysed at the indicated times post infection. Representative blot images are 
shown in Figure 24. NsP2 had delayed expression in all of the resistant isolates, and 
was detected at lower levels than TC-83 until eight hours post infection, at which time 
the expression of nsP2 begins to match that of the parental strain, Figure 25 A. At ten 
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hours post infection, the slowest of the mutant viruses, isolate 6_13_25, has increased 
levels of nsP2 compared to TC-83. If 6_13_25 is less cytotoxic, then there would be 
more live infected cells at this later time point post infection, which would leave more 
infected cells to by lysed and used for detection. At this time post infection there was no 
staining of any forms of the nonstructural polyprotein. 
When examining the expression of the E proteins, the hypothesis about isolate 
6_13_25 was correct, this isolate had a significant reduction in expression of the protein 
at 10 hours post infection, Figure 25 B. This was true for all cleavage forms of the E 
proteins. It was unclear from their sequences if the other two isolates would have any 
alterations in their expression of the structural proteins. While both 82_11_24 and 
81_12_24 had statistically significant differences in their expression of the E proteins at 
ten hours post infection, these differences are small in magnitude and not likely 
biologically significant. None of the isolates had significant changes in their expression at 
8 hours post infection, however isolate 6_13_25 had a similar trended towards reduced 





Figure 24. Representative Western blot images examining viral protein expression. Cell 
lysate was collected and used for Western blotting at the indicated times post infection. 
Lysate was probed for nsP2 and E protein as indicated, and actin was used was an 
internal loading control. Labels: U=uninfected, 1124=82_11_24, 1224=81_12_24, 
1325=6_13_25. All of the mutant viruses display a delay in nsP2 production, similar to 
their delay in growth kinetics. However, only the double mutant, 1325, showed a 
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reduction in E protein synthesis. Representative images of one experiment of three. 
Each experiment had three biological replicates per virus and uninfected control. 
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Figure 25. Quantification of viral protein expression. Using densitometry, the relative 
expression of nsP2 and the E protein was quantified. A) Quantification of nsP2 
expression at the indicated times post infection. All mutant isolates show delayed 
expression, with less nsP2 present than in TC-83 at three and five hours post infection. 
By eight hours expression has caught up, and this is maintained at ten hours. B) 
Quantification of E protein expression. There is no significant difference between the 
viruses at eight hours post infection, however at ten hours post infection both isolate 
6_13_25 and isolate 82_11_24 mutant show significant reductions in E protein 
expression compared to TC-83. Combined data from three experiments. Three biological 
replicates per group *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 as calculated using 
one way ANOVA.  
139 
Growth of VEEV TC83 and mutant isolates in a neuronal cell model 
While fibroblasts have historically been the cell of choice for much alphavirus 
work, these cells are only a model of the initial stages of infection. The severe pathology 
of VEEV, encephalitis and other neurological effects, primarily occurs in neurons and 
related cells and not in fibroblasts. Thus, it was decided to examine the mutant viral 
isolates for attenuation in a model of neuronal cells. 
The SH-SY5Y cell line was selected for several reasons. When maintained in cell 
culture they have a neural progenitor cell like phenotype and can be maintained for 
several passages which is a significant advantage over other types of neural cell culture. 
These cells can also be differentiated into a neuron like phenotype if given the correct 
additives and media203. These neuron like cells have processes and are positive for 
markers of mature neurons205.  
When growth kinetics were examined in undifferentiated SH-SY5Y cells, the 
delay in viral growth was reduced, Figure 26 A. While isolate 6_13_25 displayed a delay 
in growth, while still eventually reaching parity with TC-83, isolates 81_12_24 and 
82_11_24 did not display significant differences from TC-83. This indicates that in these 
undifferentiated neuronal cells, the reduction in the structural genes or delay in 
subgenomic RNA synthesis is playing a significant role in the delay in viral growth, while 
the N terminal region of nsP2 appears to be less important. However, in the 
differentiated cells all of the mutant viral isolates had delayed growth and isolate 
6_13_25 never reached parity with TC-83, ending the time course with a half log 
reduction in maximum titer, Figure 26 B. This shows that in these differentiated cells, 
both the N terminal region of nsP2 and the effects of the subgenomic promoter region 
are important to normal virus growth. The normal synthesis of the subgenome and the 
structural proteins is also important to reaching normal titers in these cells. This indicates 
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that the differences in physiology of the differentiated cells leads to different restrictions 
on viral growth. SH-SY5Y cells have been used as models for many different types of 
neural pathologies199,200,202,205,207, and these cells display a phenotype that is similar to 
mature neurons after differentiation. This results in many changes to the metabolism and 
biology of these cells that could restrict viral growth. This includes the production of 
various neuron specific biological markers as well as neurotransmitters, as well as a 
slowing and eventual stop of the cell cycle where these cells no longer divide. Any one 
of or combination of these changes may result in restricted and slow viral growth. For 
example, due to this slowing of the cells cycle there will be less resources present in the 
cell for the virus to use to fuel its own replication leading a slow in its replication. It is also 
possible that any of the many upregulated neural genes may also have off target effects 
that restrict viral replication. 
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Figure 26. Compound resistant mutant viruses have delayed growth in a neural cell 
model. A) Undifferentiated SH-SY5Y cells were infected with the indicated viral strains at 
either 0.05 or 5 MOI. Supernatant was collected at the indicated time points and 
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replication measured by plaque assay. In undifferentiated neural cells, there was little 
delay seen in the single mutants. However, growth of isolate 6_13_25 still showed a 
delay in growth. B) Differentiated SH-SY5Y cells were used in the same experiment as 
A. In this case all of the mutant isolates showed a delay in growth, and isolate 6_13_25 
was generally attenuated as well, with a final titer fivefold less than the parental strain. 
Graphs are of individual experiments that were performed once. Three biological 
replicates per time point collected.  
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Discussion 
While alphaviruses are well studied, there remain portions of their genomes and 
proteins that lack described function and have remained difficult to characterize using 
typical methods of investigation. In this chapter viral isolates that resist treatment with 
antiviral compounds identified and derived in our lab were used as a method of viral 
biology characterization. Through the sequencing of these isolates, mutations were 
confirmed to be in an undescribed region of VEEV nsP2. This allowed for 
characterization of these mutants as a proxy for determining the function of the region. 
Each of the isolated mutants had and additional mutation outside of the nsP 
encoding regions. Isolates 81_12_24 and 82_11_24 both had a single point mutation in 
their E proteins and isolate 6_13_25 had a mutation in the subgenomic promoter region. 
While the mutations in the E proteins had no obvious effect in our characterization of 
these isolates, the subgenomic promoter mutations had significant effects. This mutation 
resulted in decreased subgenomic RNA synthesis structural gene expression. This 
mutation is likely involved in small plaque phenotype only seen in insolate 6_13_25, as 
well its increased attenuation in growth kinetics compared to the other isolates.  
The region of nsP2 that was mutated appears to be important in normal RNA 
synthesis. As two of the isolates have delayed synthesis of positive-sense RNA. It is 
hypothesized that due to the location of these mutations in an external face of the 
protein, and far from the active helicase sites, that this region is likely involved in protein 
interactions that stabilize the nsP complex during replication. This delay in RNA 
synthesis also resulted in a delay in the expression of the viral nsPs, as indicated by 
reduced and delayed expression of nsP2. This delay would have cascading effects 
during infection. Due to its importance as a major driver of viral RNA synthesis, a 
slowing of nsP2 expression would delay RNA replication, which would result in a vicious 
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cycle of reduced RNA leading to longer delays in protein synthesis. And this would, in 
turn, explain why these viruses have delayed replication. The fact that the viruses 
overcome this attenuation later in infection to reach similar maximal titers as TC-83 is 
explained by the exponential reduction of these molecules. Eventually so much nsP2 
and RNA are created that the viral replication and production machinery, as well as the 
ribosomes, become wholly saturated, and further acceleration is not possible.  
 In addition to the work characterizing RNA replication, protein expression, and 
growth kinetics in fibroblast cells, a more restrictive neural cell line was used. SH-SY5Y 
cells are advantageous as a model because unlike other neuronal cell lines, they can be 
maintained for several passages in cell culture when kept in their immature state. This 
immature state is similar to neural progenitor cells. They can also be differentiated, 
commonly using retinoic acid, to mimic a mature neuron cell type. 
 There was no increase in attenuation when the mutant viral isolates were grown 
in the undifferentiated SH-SY5Y cells and in fact, they were more similar to TC-83 than 
in the fibroblasts. This is an interesting phenotype that deserves further study. It is 
possible that his has to with their state along the epithelial-mesenchymal axis, as these 
cells were derived from metastatic neuroblastoma that was extracted from bone marrow.  
 When these viral isolates were examined in differentiated SH-SY5Y cells, the 
attenuation was increased compared to TC-83. The growth delay was more significant 
and isolate 6_13_25 had a reduced maximum titer as well. This may be due to an 
increased basal activation level of antiviral signaling in the mature cells. However, as this 
is quite different from the undifferentiated cells, it is likely that this restriction is due to a 
change relating to the maturation of the neurons themselves. These cells have been 
found to behave in many ways like mature neurons, and it is possible that one of the 
many biochemical pathways that they activate results in the restriction of viral growth. 
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This indicates that the N terminal region of nsP2 is important for normal replication in 
these cells and should be investigated further for potential interactions with molecules 
that are expressed in these differentiated cells but not in undifferentiated SH-SY5Y cells. 
Conclusions 
From the work that has been presented here it is clear that mutations in the N 
terminal region of VEEV nsP2 are detrimental to production of new infectious virus, and 
that this results from a delay in RNA synthesis, leading to a delay in the production of the 
viral nonstructural proteins. While a detailed mechanism remains unclear, this region 
appears to be important to the RNA synthesis of the virus. The current hypothesis is that 
the mutations are disrupting the protein/protein interactions that help to form and 
stabilize the mature replicase complex, particularly between nsP2 and nsP4. This is due 
to these mutations being far from any sites known to be involved in the helicase or RNA 
binding activities of nsP2, and their localization to sites that are largely on external faces 
of the protein structure.  
This N terminal region of nsP2 is also important for replication in differentiated 
SH-SY5Y cells, but not in undifferentiated cells. This indicates that this region is likely to 
interaction with pathways or components of the mature cells that are nor expressed in 
the neuroprogenitor like cells. This should be further investigated, looking for potential 




DISUCSSION AND FUTURE DIRECTIONS 
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DISCUSSION 
This work has investigated the mechanism of action and interactions of a novel 
antiviral amidine scaffold with Venezuelan equine encephalitis virus (VEEV). These 
compounds were also used to generate mutant virus populations that were used to 
investigate heretofore unknown aspects of VEEV biology. This work has shown how 
these compounds have promise both as potential therapeutics for VEEV induced 
disease, as well as for probing biological activities of uncharacterized portions of the viral 
genome. In this manner, these compounds have future usefulness both as potential 
treatments, as well as in the development of further compounds targeting novel 
biological activities that they can be used to detect and characterize.   
The compound scaffold was characterized through the methods described in 
chapter two. It was found that these compounds specifically and efficiently inhibit the 
synthesis of VEEV RNA during infection, and that this activity is maintained in a cell free 
system. The specificity of these compounds is highly desirable, as it means there are 
less likely to be off target effects when they are moved to more complex systems such 
as animal models. The RNA synthesis inhibitory effect of these compounds is also novel 
in the development of anti-VEEV molecules, as there are no other direct RNA synthesis 
inhibitors under investigation outside of our research group and collaborators. This is 
contrasted to nucleoside analogs, which are popular drug targets, but only inhibit viral 
RNA synthesis indirectly. 
This work characterizing the antiviral activity of these compounds led to our 
hypothesis that there is a direct interaction between the compounds and the viral 
proteins. This is due to the fact that compound ML336 maintains its effectiveness in a 
cell-free RNA synthesis assay. While this assay is not able to fully confirm an interaction 
between the viral proteins and compounds due to the inclusion of some cellular 
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components, its minimal nature makes it more likely that the compounds are directly 
interfering with the viral proteins. This led to investigation described in chapter 3, 
attempting to identify and characterize this proposed interaction between the amidine 
compounds and the VEEV nsPs.  
Unfortunately, it was not possible to confirm or deny the existence of this 
interaction, as the data obtained from the experiments looking to detect this binding were 
largely inconclusive. However, there were several advances that were made through this 
work. First, a reliable method of expressing the N terminal domain of VEEV nsP2 was 
developed. While this protein was not able to be used for the full range of 
characterization studies desired, this system has been well optimized for expression, 
and large parts of its purification. Adding a useful tool for future binding kinetics assays, 
as well as biochemical experiments examining the effects of these compounds on the 
enzymatic activities of the N terminal region of nsP2.  
Additionally, a technique using fluorescent microscopy with a double stranded 
RNA antibody as a readout for active viral replication was performed for the first time in 
our lab. This tool allows for the detection of both localization of the replication activity of 
this virus in infected cells, and quantification of how many cells are undergoing active 
viral production at any given time during infection, as opposed to cells that may no 
longer contain actively replicating virus, but still express viral proteins. For this same 
assay, click chemistry compatible compounds were developed by our medicinal chemist 
collaborator, opening up many new avenues for compound manipulation. The modified 
functional groups of these compounds allow for a variety of detection methods, as 
described here, as well as purification of the compounds from complex mixtures, as has 
been previously performed with labeled proteins215, depending on the desired use.  
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In addition to being useful for therapeutic development, antiviral compounds can 
also be used as chemical probes of viral biology. These compounds can be used to 
generate resistant mutant viral isolates, and these mutations can then be mapped to the 
viral genome, indicating the region(s) that are important in the activity of the compounds. 
This is useful from both a drug mechanism standpoint as well as a viral biology 
standpoint. For example, in this work it has been shown that the amidine antiviral 
scaffold functions to inhibit viral RNA synthesis. This means that any mutations that 
occur in the viral genome which confer resistance to drug treatment are in areas that are 
likely to be highly important for the synthesis of viral RNA. When these experiments 
were performed using the amidine scaffold compounds, it was found was that the 
resistance mutations consistently mapped to the N terminal domain of VEEV nsP2, a 
region of currently undescribed function.  
The localization of mutations to this region is not altogether surprising, as nsP2 is 
highly important in viral RNA synthesis, acting as the viral RNA helicase. NsP2 is also 
responsible for the normal cleavage of the polyprotein, which regulates RNA synthesis 
during viral infection216–219. As the implicated region lacked a specific function it was 
hypothesized that it was involved the normal synthesis of viral RNA. Due the location of 
the mutations on an external face of the protein, as well as the mutations being found 
primarily in less ordered regions, this activity was predicted to be mediated by interfering 
with the protein/protein interactions of the replicase complex and destabilizing these 
interactions.  
A group of mutant isolates was selected and submitted for further 
characterization studies. First, it is important to point out that these mutations were not 
found in detectable levels in unselected viral populations, indicating that these mutations 
are likely to be detrimental to the virus in the absence of selection by the compound. 
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Initially these viral isolates were examined in a growth curve using highly permissive 
fibroblast cells, this experiment showed that the compound resistant isolates had 
delayed growth compared to the parental VEEV strain used, but they did reach the same 
peak titers late in infection. This result was then mirrored in their RNA synthesis profiles 
with the mutants having delayed synthesis of both positive and negative sense genomic 
RNA.  
Three mutant viruses were selected for further characterization. Two isolates 
contained only single point mutations in nsP2 as well as a single point mutation in their E 
proteins. These isolates were predicted to be attenuated and display alterations in their 
RNA synthesis. A third isolate had a double mutation in nsP2 as well as a point mutation 
in its subgenomic promoter region. This isolated was predicted to be highly attenuated 
due to expected changes in the synthesis of its subgenomic RNA, and it was unclear 
how the mutations in nsP2 would combine with this to effect RNA synthesis and viral 
replication. 
Each of these viruses was attenuated in fibroblast cells, having delayed growth 
compared to the parental strain. As predicted the isolate containing the mutation in the 
subgenomic promoter was strongly attenuated, with the other two isolates having 
intermediate phenotype. However, it was surprising that each these isolates eventually 
reached parity with the parental strain and had no reduction in maximum titer. Similar 
phenotypes were seen when RNA synthesis was examined, and as predicted, the 
isolate with the subgenomic promoter mutation had a decrease in subgenomic RNA 
synthesis that the other two isolates did not display. The effects of these mutations on 
protein expression were slightly different, each of the isolates had a significant delay in 
the production of the viral nsPs and did not reach parental expression levels until eight 
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hours post infection. As expected, only the subgenomic promoter mutation had an effect 
on the synthesis of the structural proteins. 
When combined this data indicates that mutations in the N terminal region of 
nsP2 lead to delays in RNA synthesis leading to delays in nsP expression. As the nsPs 
are responsible for the replication of the viral RNA, these effects compound during 
infection, slowing viral replication, and leading to the delayed growth that was seen. 
However, as there was no loss in titer, and expression levels of both RNA and protein 
reach parity with TC-83 later in infection, these effects are overcome. This is most likely 
due to the nature of the exponential production of viral materials during infection. Even 
though the log phase growth of the virus is delayed, the viruses are still able to produce 
enough of their components over time to saturate their replicative systems as well as 
those of the cell, at which point no more acceleration of replication is possible. This 
results in the maximum titer being achieved, even though it takes longer to reach. A 
model outlining this hypothesis can be found in Figure 27. 
These phenotypes had all been examined in a highly permissive fibroblast cell 
line. These cells lack the ability to activate their interferon system and so are unable to 
enter an antiviral state. It was hypothesized that the mutant viral isolates would be 
increasingly attenuated in a cell system that could activate the antiviral response, so a 
second cell line was selected to examine this. SH-SY5Y cells were selected. These cells 
have a neural progenitor cell like phenotype and can also be differentiated into a mature 
neuron like state, making them an excellent model of VEEV infection in neurons, a 
significant site of pathology in the host220,221.  
The growth kinetics of the mutant viral isolates were examined in both the 
differentiated and undifferentiated cells. In the immature cells, the growth delay was less 
significant than that seen in the fibroblast cells. Only the isolate containing the 
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subgenomic promoter mutation was found to have a significant delay compared to TC-
83 and as before it still reached parity alter in infection. However, in the differentiated 
cells each of the isolates was significantly attenuated, and the isolates with the 
subgenomic promoter mutation had a final titer reduction of fivefold. This difference 
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Figure 27. Working model of the effects of mutations in the N-terminal region of VEEV 
nsP2. A) Early in infection the nonstructural polyprotein is synthesized from the genomic 
RNA. However, due the presence of mutations, the protein interactions have reduced 
stability, resulting in a significant reduction in the number of active complexes. This 
reduces the rate of viral RNA synthesis. B) As infection proceeds to later time points, the 
amount of nsPs synthesized increases. This increases the number of complexes that 
form despite the reduction in interaction stability. This leads to an increase in the rate of 
viral RNA synthesis, eventually reaching the maximum rate seen in infection with the 
parental TC-83 strain. 
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between the differentiated and undifferentiated cells implies that the N terminal region of 
nsP2 is likely important to the normal replication of VEEV in mature neurons but not in 
other neural derived cells, such a neural progenitor cells. The differentiated cells go 
through significant physiological changes during the maturation process leading to a 
host of phenotypes that make them useful models for neurological disease200,202,207,221. 
This includes the production of neurotransmitter, the formation of neural processes, and 
loss of cell cycling behavior. Any one or multiple of these changes could lead to more 
restricted replication of VEEV. Of particular interest is the way that the senescence of 
these cells may restrict the amount of resources available for viral replication, which is 
likely to perturb the ability of the virus to replicate as quickly as it would in the dividing 
undifferentiated cells.  
To summarize the work presented in this dissertation, the amidine scaffold 
compounds developed by our lab for the treatment of VEEV are highly effective and 
specific at inhibiting VEEV RNA synthesis. This activity is maintained in a cell-free 
system and has no effect on cellular RNA. These compounds are currently being used 
as the foundation for pretherapeutic drug discovery and development with collaborators. 
These compounds are predicted to interact with the nsPs of VEEV. While this interaction 
remains unconfirmed, several useful biochemical assays were developed, and can be 
used for further characterization of both antiviral compounds and viruses. A system was 
also developed for the recombinant expression of the N terminal region of nsP2, and this 
system is ready for use in biochemical and pharmacological assays. The amidine 
compounds were also used to derive resistant viral isolates that were used to 
characterize the N terminal region of VEEV vsP2. It was found that this region is 
important to the synthesis of viral RNA, and that its perturbation leads to a delay in viral 
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growth. This region is also important in the infection of differentiated neurons, but not 
undifferentiated neuronal cells. The mechanism of this phenotype remains unknown.  
FUTURE DIRECTIONS 
The work presented here has left several unanswered questions that need to be 
further examined and opened new questions.  
First, it remains unclear how and if the amidine scaffold compounds are 
interacting with the proteins of VEEV. While the sequencing results from chapter 4 
clearly indicate that mutations occur in a predictable manner to escape compound 
treatment, it has yet to be shown that the compounds and viral proteins directly interact. 
In chapter 3 several methods that were used to attempt to describe this interaction were 
summarized. However, no conclusive results were obtained. The primary way that this 
work should be continued is continuing to pursue the use of ectopically expressed 
protein for use in biochemical and pharmacological assays.  
The production of the N terminal region of nsP2 in a soluble form has been well 
optimized as has its initial purification. Further work remains in optimizing the cleavage 
of the SUMO tag from the construct, which will be necessary for any functional assays to 
be performed, such as helicase activity assays. The currently expressible protein is 
already usable in many types of binding assays such a microscale thermophoresis or 
surface plasmon resonance. While each of these assays requires highly pure sample, 
tag removal is not necessary so the current construct can be used. Pilot studies using 
SPR have been performed, however sensitivity was poor and further optimization of this 
assay is required.  
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Secondly, the work with the resistant viral isolates has shown that as expected, 
the N terminal region of nsp2 appears to be important to viral RNA synthesis. However, 
each of the isolates tested had an additional mutation. The N terminal region needs to 
be isolated to confirm that these phenotypes are due to the mutations in this region. To 
do this, a reverse genetic system can used. Plasmid based clones of TC-83 are 
available, and the desired mutations can be inserted using site directed mutagenesis. 
With the use of in vitro transcription these plasmids can be transfected into cells and 
virus generated with the desired genotypes. These viruses can then be submitted to the 
same experimenters as already performed with the mutant viral isolates. This type of 
system can also be used to isolate the double nsP2 mutation seen in one isolate, which 
was confounded by the presence of a mutation in its subgenomic promoter.  
Finally, the work with the resistant viral isolates in neuronal cells indicated that 
the N terminal region of VEEV nsP2 is important for the normal infection of differentiated 
neurons. The effect of mutating this region was more significant in these cells than an 
either fibroblasts or undifferentiated neuronal cells. This lead to the hypothesis that a 
feature unique to the differentiated neural cells was involved in this enhanced restriction 
on viral replication. This should first be investigated by examining the differential gene 
expression of the differentiated and undifferentiated cells to determine their differences 
in gene expression that may explain this alteration in sensitivity to viral infection. Further 
transcriptional changes in response to infection can then be determined by performing 
single cell sequencing and isolating those genes that upregulated in the infected but not 
uninfected cells, to characterize the response to infection. Ideally, there will be known 
antiviral signals or vial interactions that can be pursued in further, more detailed 
experiments. If not, there are a variety of ways that protein interactions can be predicted 
to lead to potential genes of interest. 
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